

1 **Persistent oxidative stress and inflammasome activation in**  
2 **CD14<sup>high</sup>CD16<sup>-</sup> monocytes from COVID-19 patients**

3

4 Silvia Lucena Lage<sup>1\*§</sup>, Eduardo Pinheiro Amaral<sup>2\*§</sup>, Kerry L. Hilligan<sup>2,3</sup>,  
5 Elizabeth Laidlaw<sup>1</sup>, Adam Rupert<sup>4</sup>, Sivaranjani Namasivayan<sup>2</sup>, Joseph  
6 Rocco<sup>1</sup>, Frances Galindo<sup>1</sup>, Anela Kellogg<sup>5</sup>, Princy Kumar<sup>6</sup>, Rita Poon<sup>6</sup>, Glenn  
7 W. Wortmann<sup>7</sup>, John P. Shannon<sup>8</sup>, Heather D. Hickman<sup>8</sup>, Andrea Lisco<sup>1</sup>,  
8 Maura Manion<sup>1</sup>, Alan Sher<sup>2</sup>, Irini Sereti<sup>1</sup>

9

10 <sup>1</sup>HIV Pathogenesis Section, Laboratory of Immunoregulation, National  
11 Institute of Allergy and Infectious Diseases, National Institutes of Health,  
12 Bethesda, MD, USA.

13 <sup>2</sup>Immunobiology Section, Laboratory of Parasitic Diseases, National Institute  
14 of Allergy and Infectious Diseases, National Institutes of Health, Bethesda,  
15 MD, USA.

16 <sup>3</sup>Immune Cell Biology Programme, Malaghan Institute of Medical Research,  
17 Wellington 6012, New Zealand.

18 <sup>4</sup>AIDS Monitoring Laboratory, Frederick National Laboratory for Cancer  
19 Research, Leidos Biomedical Research, Inc, Frederick, MD, USA.

20 <sup>5</sup>Clinical Monitoring Research Program, Frederick National Laboratory for  
21 Cancer Research, Leidos Biomedical Research, Inc, Frederick, MD, USA.

22 <sup>6</sup>Division of Infectious Diseases and Travel Medicine at MedStar Georgetown  
23 University Hospital, Washington DC, USA.

24 <sup>7</sup>Section of Infectious Diseases, MedStar Washington Hospital Center,  
25 Washington, DC, USA.

1 <sup>8</sup>Viral Immunity and Pathogenesis Unit, Laboratory of Clinical Immunology  
2 and Microbiology, National Institutes of Allergy and Infectious Diseases,  
3 National Institutes of Health, Bethesda, MD, USA.

4

5 **Running title:** Oxidative stress-associated inflammasome activation in  
6 COVID-19.

7

8 **\*Corresponding authors**

9 Silvia Lucena Lage, PhD

10 Email: [silvia.lage@nih.gov](mailto:silvia.lage@nih.gov)

11 Telephone number: 240-669-5508

12 10 Center Drive, Bldg.10, Room 11B15, Bethesda MD, 20892

13

14 Eduardo Pinheiro Amaral, PhD

15 Email: [eduardo.amaral@nih.gov](mailto:eduardo.amaral@nih.gov)

16 Telephone number: 301.761.7400

17 33 North Dr, Room 1W10A, Bethesda MD, 20892

18

19 **§ These authors contributed equally to this work.**

20

21

## 1 **ABSTRACT**

2 The poor outcome of the coronavirus disease-2019 (COVID-19), caused by  
3 SARS-CoV-2, is associated with systemic hyperinflammatory response and  
4 immunopathology. Although inflammasome and oxidative stress have  
5 independently been implicated in COVID-19, it is poorly understood whether  
6 these two pathways cooperatively contribute to disease severity. Herein, we  
7 found an enrichment of CD14<sup>high</sup>CD16<sup>-</sup> monocytes displaying inflammasome  
8 activation evidenced by caspase-1/ASC-speck formation in severe COVID-19  
9 patients when compared to mild ones and healthy controls, respectively.  
10 Those cells also showed aberrant levels of mitochondrial superoxide  
11 (MitoSOX) and lipid peroxidation, both hallmarks of the oxidative stress  
12 response, which strongly correlated with caspase-1 activity. In addition, we  
13 found that NLRP3 inflammasome-derived IL-1 $\beta$  secretion by SARS-CoV-2-  
14 exposed monocytes *in vitro* was partially dependent on lipid peroxidation.  
15 Importantly, altered inflammasome and stress responses persisted after short-  
16 term patient recovery. Collectively, our findings suggest oxidative  
17 stress/NLRP3 signaling pathway as a potential target for host-directed therapy  
18 to mitigate early COVID-19 hyperinflammation as well as its long-term  
19 outcomes.

20

21 Keywords: COVID-19, NLRP3 inflammasome, Oxidative stress, Lipid  
22 peroxidation, CD14<sup>high</sup>CD16<sup>-</sup> monocytes.

23

## 1 INTRODUCTION

2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the  
3 causative agent of coronavirus disease 2019 (COVID-19), emerged in late  
4 2019 and rapidly spread worldwide, leading to approximately 3.6 million  
5 deaths to date (WHO, 2021). Although the majority of infected individuals are  
6 asymptomatic or experience mild disease, about 20% of patients with COVID-  
7 19 develop moderate/severe manifestations mainly characterized by hypoxia  
8 and extensive pneumonia (Wu et al., 2020). Patients occasionally progress to  
9 critical condition as a result of pathological complications related to acute  
10 respiratory distress syndrome (ARDS), endothelial dysfunction and  
11 coagulopathy, leading to multi-organ failure and consequently death  
12 (Ackermann et al., 2020; Bonaventura et al., 2021; Dandel, 2021; Gibson et  
13 al., 2020).

14 Although the factors involved in disease progression to severe forms  
15 remain poorly understood, an exacerbated inflammatory response has been  
16 implicated as a major cause of morbidity and mortality in patients with COVID-  
17 19 (Hojyo et al., 2020; Tang et al., 2020). Overall, elevated levels of  
18 circulating inflammatory markers including C-reactive protein (CRP), ferritin,  
19 D-dimer and a wide range of inflammatory cytokines/chemokines have been  
20 associated with poor disease outcome. Importantly, the pro-inflammatory  
21 cytokines IL-1 $\beta$  and IL-18 have both been implicated in lung injury and  
22 respiratory distress induced by SARS-CoV-2 (Conti et al., 2020; Meduri et al.,  
23 1995; Satis et al., 2021). Of note, mature IL-1 $\beta$  plays an important role in  
24 immune cell recruitment to the site of infection as well as in stimulating cells to  
25 produce and release a number of inflammatory mediators including IL-6 and

1 CRP (Patton et al., 1995; Slaats et al., 2016). In addition, mature IL-18 has  
2 also been associated with hyperferritinemia and cytopenias, both pathological  
3 features observed in COVID-19 patients displaying severe disease  
4 (Agbuduwe and Basu, 2020; Perricone et al., 2020).

5 IL-1 $\beta$  and IL-18 production rely on inflammasome activation upon  
6 sensing of pathogen/damage-associated molecular patterns (PAMPs/DAMPs)  
7 by distinct innate immune intracellular sensors (Martinon et al., 2002; Sharma  
8 and Kanneganti, 2016). Once activated, those sensors recruit the adapter  
9 molecule ASC (apoptosis-associated speck-like protein containing a caspase  
10 activating and recruitment domain, CARD) in order to activate pro-caspase-1,  
11 thus forming the inflammasome complex also known as ASC-speck (Lu et al.,  
12 2014). The enzymatic activity of caspase-1 is required for IL-1 $\beta$  and IL-18  
13 processing and secretion as well as for the cleavage of the pore-forming  
14 protein gasdermin D (GSDMD), thus inducing a cell death process called  
15 pyroptosis (Broz et al., 2010; Shi et al., 2015).

16 Among the distinct cytosolic sensors able to form inflammasomes the  
17 molecule NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) has  
18 been implicated in COVID-19 (Abais et al., 2015; Freeman and Swartz, 2020;  
19 Rodrigues et al., 2021; Shah, 2020). Several stress-related cellular processes  
20 have been reported to induce NLRP3 activation in response to distinct PAMPs  
21 and DAMPs, such as K<sup>+</sup> efflux (Munoz-Planillo et al., 2013), lysosomal  
22 disruption (Hornung et al., 2008), mitochondrial damage (Iyer et al., 2013;  
23 Zhou et al., 2011) and the generation of reactive oxygen species (ROS)  
24 (Martinon, 2010; Tschopp and Schroder, 2010). Since robust redox responses  
25 observed in hypoxic conditions during other pulmonary infections are

1 commonly associated with exacerbated cytokine production and disease  
2 progression (Amaral et al., 2021; Erlich et al., 2020; Favier et al., 1994;  
3 Freeborn and Rockwell, 2021; Pohanka, 2013; Prabhakar et al., 2020), host  
4 oxidative stress has also been implicated in the pathogenesis of COVID-19  
5 (Delgado-Roche and Mesta, 2020; Fakhri et al., 2020; Ntyonga-Pono, 2020).

6       Oxidative stress results from the imbalance of total oxidant status over  
7 antioxidant response (Bhat et al., 2012). Aberrant generation of ROS along  
8 with accumulation of toxic lipid peroxides can be detrimental to host cells and  
9 thus promote tissue damage. The inability of cells to detoxify biological  
10 membranes from lipid peroxidation is caused by a decrease in the enzymatic  
11 activity of glutathione peroxidase-4 (Gpx4) often due to reduced intracellular  
12 levels of its co-factor glutathione (GSH). Of note, a decrease in GSH levels  
13 has been reported in several comorbidities including type-2 diabetes  
14 (Goutzourelas et al., 2018; Lutchmansingh et al., 2018; Sekhar et al., 2011;  
15 Tan et al., 2012), obesity, cardiovascular disorders (Cavalca et al., 2009;  
16 Chaves et al., 2007; Shimizu et al., 2004), respiratory diseases (Fitzpatrick et  
17 al., 2012; Fitzpatrick et al., 2011; Fitzpatrick et al., 2009; Rahman and  
18 MacNee, 1999) cancer (Balendiran et al., 2004; Traverso et al., 2013) and  
19 hepatitis (Burgunder and Lauterburg, 1987; Shaw et al., 1983), most of which  
20 have been recognized as risk factors for the severe outcome of COVID-19.  
21 Moreover, it is possible that uncontrolled oxidative stress in the lung may form  
22 a positive feedback loop exacerbating NLRP3-inflammasome activation the  
23 production of pro-inflammatory cytokines such as IL-1 $\beta$ . In addition, the  
24 dysregulation of the cellular antioxidant response controlling lipid peroxidation  
25 may represent a potential host factor to be targeted to prevent aberrant

1 inflammatory responses. However, the possible interplay of these two  
2 important inflammatory responses has not been formally investigated at the  
3 cellular level in COVID-19 patients.

4         Here, we assessed inflammasome and oxidative stress activation in  
5 circulating blood monocytes from COVID-19 patients and investigated  
6 whether these cellular pathways cooperatively contribute to COVID-19  
7 disease severity and cytokine release syndrome. Our findings provide insights  
8 into the pathogenesis of COVID-19, both during acute infection and early  
9 recovery, suggesting inhibition of both NLRP3-inflammasome activation and  
10 lipid peroxidation as potential therapeutic interventions in COVID-19.

11

## 1   **RESULTS**

### 2   **Significant changes in circulating monocyte subsets in COVID-19** 3   **patients**

4           Dysregulated activation of the mononuclear phagocyte compartment  
5 leads to pathological inflammation and has been implicated in COVID-19  
6 severity (Merad and Martin, 2020). We first investigated phenotypic changes  
7 in circulating blood monocytes from healthy control individuals (HCs) and  
8 COVID-19 patients experiencing mild or moderate-severe disease. Patients  
9 enrolled in this study were classified according to their oxygen requirement at  
10 the time of the research blood draw as (1) mild for patients requiring less than  
11 4 Liters of oxygen (including no oxygen needed) (n=31; 23 inpatients and 8  
12 outpatients, respectively), (2) moderate (n=4) for subjects who required up to  
13 50% oxygen concentration, and (3) severe (n=12) for patients with a fraction of  
14 inspired oxygen (FiO<sub>2</sub>) over 50% or admitted to ICU care. We pooled patients  
15 displaying moderate and severe forms of the disease in the same group,  
16 which we named moderate-severe. Two patients remain in the critical care  
17 unit and one participant died by the time the study was completed. In addition,  
18 14 patients were followed longitudinally after a short-term recovery period  
19 (approximately 52 days after infection onset), and 2 subjects were recruited  
20 after recovery. Clinical and demographic features of patients enrolled in the  
21 study are summarized in **Table 1**.

22           We observed that COVID-19 patients displayed a striking depletion of  
23 the patrolling CD14<sup>low</sup>CD16<sup>+</sup> subset (Figure 1A-B) accompanied by  
24 enrichment of the CD14<sup>high</sup>CD16<sup>-</sup> classical/inflammatory monocytes compared

1 to HCs (Figure 1A and 1C). Moreover, CD14<sup>high</sup>CD16<sup>-</sup> classical monocytes  
2 from COVID-19 patients showed downmodulation of HLA-DR and of the C–C  
3 chemokine receptor type 2 (CCR2) (Figure 1D and 1E, respectively).  
4 However, none of these features were associated with disease severity, since  
5 similar frequency of monocyte subsets and surface markers were observed  
6 when COVID-19 patients were grouped in mild and moderate-severe disease  
7 categories (Figure 1F-I). Collectively, these results demonstrate phenotypical  
8 and proportional changes in the peripheral monocytic compartment during  
9 SARS-CoV-2 infection consistent with previous reports (Wilk et al., 2020;  
10 Zhou et al., 2021)

## 11 **Systemic inflammasome activation during COVID-19 is associated with** 12 **disease severity**

13 Systemic inflammation has been considered as a hallmark of COVID-  
14 19 severity (Hojyo et al., 2020). Accordingly, several molecular measurements  
15 associated with systemic inflammation including CRP, D-dimers, ferritin and  
16 IL-6 were elevated in plasma from COVID-19 patients in our cohort (Table 2  
17 and Supplemental Figure 1). Additional analysis of these inflammatory  
18 markers failed to discriminate disease severity in this patient cohort  
19 (Supplemental Table 1). It is important to highlight that the COVID-19 patients  
20 were enrolled in the mild group based on their lower oxygen requirement  
21 (nasal cannula 4 Liters or less or no oxygen), which differs from other studies  
22 where only outpatients displaying no oxygen requirement were assigned as  
23 mild patients.

24 In addition to the above mentioned inflammatory markers, the

1 inflammasome-derived cytokine IL-18 has also been implicated in COVID-19-  
2 associated pathological inflammation (Conti et al., 2020; Meduri et al., 1995;  
3 Satis et al., 2021). Accordingly, we observed higher plasma levels of IL-18 in  
4 our cohort of COVID-19 patients when compared to HCs (Figure 2A),  
5 suggesting systemic inflammasome activation in this group of patients. Since  
6 drastic depletion of the patrolling monocytes subset along with increased  
7 levels of classical/inflammatory CD14<sup>high</sup>CD16<sup>-</sup> monocytes were observed in  
8 COVID-19 patients, we evaluated whether CD14<sup>high</sup>CD16<sup>-</sup> cells represent a  
9 source of inflammasome activation during COVID-19. To do so, peripheral  
10 blood mononuclear cells (PBMCs) from HCs and patients were incubated with  
11 FLICA, an approach widely used to measure caspase-1/4/5 activity. We  
12 observed higher caspase-1/4/5 activity within the classical monocyte subset  
13 from COVID-19 patients when compared to HCs (Figure 2B), suggesting this  
14 cell subset contributes to IL-1 $\beta$  and IL-18 maturation during COVID-19.

15 To directly evaluate inflammasome complex formation in  
16 CD14<sup>high</sup>CD16<sup>-</sup> monocytes, we screened classical monocytes from HCs and  
17 COVID-19 patients for active ASC aggregates by imaging flow cytometry,  
18 following a previously described protocol (Lage et al., 2019). Briefly, PBMCs  
19 were pre-incubated with FLICA for caspase-1 detection followed by  
20 immunophenotyping and intracellular ASC staining. Using this approach, we  
21 identified monocytes with cytosolic ASC speck formation associated with  
22 active caspase-1/4/5, represented by FLICA<sup>+</sup>ASC-speck<sup>+</sup> cells (Figure 2C,  
23 Merge panel). The summary data in Figure 2D demonstrate a substantially  
24 higher frequency of classical monocytes showing FLICA<sup>+</sup>ASC-speck<sup>+</sup>  
25 formation in COVID-19 patients than HC subjects, which positively correlated

1 with plasma IL-18 levels (Figure 2E). Importantly, in contrast to the other  
2 plasma inflammatory markers tested in this study (Supplemental Table 1), the  
3 percentage of monocytes with inflammasome complex formation and plasma  
4 levels of the downstream cytokine IL-18 were both significantly increased in  
5 the moderate-severe group than in patients with milder symptoms (Figure 2F  
6 and 2G, respectively), highlighting a role for inflammasomes in COVID-19  
7 severity. Of note, inflammasome activation in circulating classical monocytes  
8 was not associated with age, sex, BMI, or race in our group of patients  
9 (Supplemental Figure 2).

10 Consistent with systemic inflammation, COVID-19-derived PBMCs but  
11 not HC cells spontaneously released IL-1 $\beta$ , as well as IL-6 and TNF- $\alpha$  *ex vivo*  
12 (Figure 3A, 3B and 3C, respectively). We next tested the effect of MCC950, a  
13 specific inhibitor of the NLRP3 inflammasome, and colchicine, an anti-  
14 inflammatory compound, on spontaneous cytokine release from COVID-19  
15 patient cells. In addition to other anti-inflammatory effects, colchicine has  
16 been shown to inhibit microtubule-driven spatial arrangement of mitochondria,  
17 thus preventing full NLRP3 inflammasome activation (Misawa et al., 2013)  
18 and its use has been also reported to have beneficial effects in outpatients but  
19 not in hospitalized COVID-19 patients in recent clinical trials (Horby et al.,  
20 2021; Lopes et al., 2021; Tardif et al., 2021). Despite the promising clinical  
21 use of colchicine to prevent inflammasome activation, we did not observe any  
22 effect of compound on cytokine release by patient-derived PBMCs *in vitro*  
23 (Figure 3D-F). Conversely, selective inhibition of the inflammasome sensor  
24 NLRP3 by MCC950 specifically abolished IL-1 $\beta$  secretion *ex vivo* by PBMCs  
25 from COVID-19 patients without impacting IL-6 and TNF- $\alpha$  production (Figure

1 3D, 3E and 3F, respectively). Collectively, our findings support a role for  
2 NLRP3-mediated ASC-speck formation and caspase-1 activation in  
3 pathologic inflammation associated with moderate and severe forms of  
4 COVID-19.

5 **CD14<sup>high</sup>CD16<sup>-</sup> monocytes from COVID-19 patients exhibit prominent**  
6 **oxidative stress activity**

7 Oxidative stress has been suggested to be a critical host factor in  
8 driving immune response exacerbation in several infectious diseases (Amaral  
9 et al., 2021; Erlich et al., 2020; Favier et al., 1994; Freeborn and Rockwell,  
10 2021; Pohanka, 2013). However, the induction of inflammatory oxidative  
11 stress responses in circulating monocytes obtained from COVID-19 patients  
12 has not been formally investigated. First, we sought to investigate the  
13 systemic oxidative response in plasma obtained from our cohort of COVID-19  
14 patients by measuring the levels of ferritin heavy chain, catalase, total  
15 superoxide dismutase (SOD) activity, total antioxidant status, iron and lipid  
16 peroxidation (Figure 4A-F). Interestingly, elevated plasma levels of ferritin  
17 (Figure 4A), catalase (Figure 4B) superoxide dismutase (Figure 4C) and lipid  
18 peroxidation (Figure 4F) were found in COVID-19 patients compared to HC  
19 individuals whereas no significant difference was observed in the levels of  
20 total antioxidant response (Figure 4D) and iron (Figure 4E) in the same set of  
21 samples.

22 Mitochondrial superoxide is an important intracellular source of reactive  
23 oxygen species and plays a critical role in promoting Fenton/Haber-Weiss  
24 reactions by releasing iron from intracellular ferritin complex, which in turn

1 culminates in the generation of highly reactive hydroxyl radicals (Biemond et  
2 al., 1986; Biemond et al., 1984; Bou-Abdallah et al., 2018; Monteiro and  
3 Winterbourn, 1988; Williams et al., 1974). Elevated levels of hydroxy radicals  
4 in turn lead to abnormal generation and accumulation of toxic lipid peroxides  
5 affecting host cell function and viability. To carefully assess oxidative stress  
6 response in COVID-19 patients at the cellular level, we evaluated  
7 mitochondrial superoxide generation and lipid peroxidation in circulating  
8 CD14<sup>high</sup>CD16<sup>-</sup> monocytes from COVID-19 patients (n=40) and HCs (n=23) by  
9 flow cytometric analysis. In addition, we used PBMC lysates from COVID-19  
10 patients and HCs to investigate the host cellular antioxidant response by  
11 assessing intracellular levels of glutathione. We found elevated levels of  
12 mitochondrial superoxide along with aberrant lipid peroxidation in  
13 CD14<sup>high</sup>CD16<sup>-</sup> monocytes from COVID-19 patients compared to HCs (Figure  
14 4G and 4H, respectively). Consistent with these observations, a major  
15 reduction in intracellular glutathione levels was observed in PBMC lysates  
16 from COVID-19 patients compared to HCs (Figure 4I), suggesting an impaired  
17 intracellular host antioxidant response to control oxidative stress responses  
18 and ultimately lipid peroxidation.

## 19 **Exacerbated inflammasome activation is associated with mitochondrial** 20 **dysfunction in COVID-19 patients**

21 We next sought to evaluate associations between cellular inflammatory  
22 responses and oxidative stress in monocytes from COVID-19 patients and  
23 HCs. We found strong negative correlations between lipid peroxidation,  
24 mitochondrial superoxide and inflammasome activation and the frequency of

1 CD14<sup>low</sup>CD16<sup>+</sup> monocytes as well as CCR2 expression on CD14<sup>high</sup>CD16<sup>-</sup>  
2 monocytes (Figure 5A). A highly significant negative correlation between  
3 glutathione levels and lipid peroxidation along with ASC-specks was also  
4 observed (Figure 5A), suggesting a possible link between cell stress  
5 responses and inflammasome activation during COVID-19.

6 Monocyte secretion of IL-1 $\beta$  and IL-18 as a result of NLRP3  
7 inflammasome activation requires mitochondrial-derived ROS and is  
8 commonly associated with an imbalance of cellular redox status (Martinon,  
9 2010; Tschopp and Schroder, 2010). To assess the level of mitochondrial  
10 perturbation on monocytes isolated from COVID-19 patients, we incubated  
11 total PBMC with MitoTracker probe in order to evaluate mitochondrial  
12 membrane potential ( $\Delta\Psi_m$ ) in CD14<sup>high</sup>CD16<sup>-</sup> monocytes by imaging flow  
13 cytometry. This approach was also employed to address whether  
14 mitochondrial perturbation or dysfunction is associated with inflammasome  
15 assembly measured here by ASC-speck formation. CD14<sup>high</sup>CD16<sup>-</sup> monocytes  
16 from COVID-19 patients were grouped according to their ASC-speck status in  
17 CD14<sup>high</sup>ASC-speck<sup>neg</sup> (resting cells) and CD14<sup>high</sup>ASC-speck<sup>pos</sup> cells and the  
18 loss of mitochondrial membrane potential was determined a decrease in  
19 MitoTracker MFI (Figure 5B). ASC-speck<sup>pos</sup> monocytes showed an elevated  
20 frequency of cells displaying small puncta of MitoTracker staining compared  
21 to ASC-speck<sup>neg</sup> cells (Figure 5C). In contrast, decreased MitoTracker gMFI  
22 was found in cells displaying ASC speck formation (Figure 5D), demonstrating  
23 loss of mitochondrial membrane potential and inflammasome activation in  
24 CD14<sup>high</sup>CD16<sup>-</sup> monocytes.

1 Mitochondrial dysfunction is also linked with a metabolic shift from  
2 OXPHOS to glycolysis in inflammatory immune cells (Angajala et al., 2018;  
3 Monteiro et al., 2020). To investigate whether monocytes obtained from  
4 COVID-19 patients display this metabolic shift, we stained cells for Glut-1.  
5 Supporting our MitoTracker results, we found that CD14<sup>high</sup>CD16<sup>-</sup> monocytes  
6 from COVID-19 patients showed elevated levels of Glut-1 (Supplemental  
7 Figure 3A), suggesting that these cells are undergoing intense cellular stress,  
8 reflecting by altered cell metabolism. Further, we found no difference in Glut-1  
9 level when patients were grouped based on their disease severity status  
10 (Supplemental Figure 3B).

### 11 **Aberrant oxidative stress response strongly correlates with robust** 12 **caspase-1 activation in COVID-19 patients**

13 We have shown that COVID-19 patients display elevated caspase-1  
14 activity and accumulation of lipid peroxides in circulating CD14<sup>high</sup>CD16<sup>-</sup>  
15 monocytes. As the oxidative stress response expressed by lipid peroxidation  
16 also modulates NLRP3-inflammasome activation and the consequent release  
17 of mature IL-1 $\beta$  and IL-18 (Martinon, 2010; Tschopp and Schroder, 2010), we  
18 extended our analyses to explore the correlation between inflammasome  
19 activation and the oxidative stress response and their impact on disease  
20 severity.

21 We first investigated whether levels of mitochondrial superoxide in  
22 COVID-19 patients correlate with caspase-1 activity. As shown in Figure 5E we  
23 observed a significant positive correlation between mitoSOX (gMFI) and  
24 FLICA (gMFI) in CD14<sup>high</sup>CD16<sup>-</sup> monocytes from COVID-19 patients. In

1 addition, we found a robust positive correlation between lipid peroxidation and  
2 active caspase-1 (Figure 5F). To test whether these parameters can reflect  
3 clinical disease severity, we stratified patients into mild or moderate-severe  
4 groups. We found a significant positive correlation of mitochondrial superoxide  
5 production and caspase-1 activity in monocytes from patients displaying mild  
6 and moderate/severe disease (Figure 5G). However, a stronger and more  
7 robust correlation was observed between lipid peroxidation and caspase-1  
8 activity in patients in the moderate-severe group than those in the mild group  
9 (Figure 5H). Collectively, these findings reveal that CD14<sup>high</sup>CD16<sup>-</sup> monocytes  
10 from COVID-19 patients display dysregulated oxidative stress responses and  
11 prominent inflammasome activation. Crosstalk between these two pathways  
12 may negatively impact the clinical course of SARS-CoV-2-infected subjects.

13 **IL-1 $\beta$  secretion by human monocytes in response to SARS-CoV-2 in**  
14 **vitro requires NLRP3 inflammasome activation and is partially**  
15 **dependent on lipid peroxidation**

16 We next sought to investigate the crosstalk between the oxidative  
17 stress pathway and NLRP3-caspase-1 activation on circulating blood  
18 monocytes during COVID-19. To do so, we incubated column-purified  
19 monocytes isolated from healthy donors with SARS-CoV-2 USA-WA1/2020 at  
20 different multiplicities of infection (MOI) and measured IL-1 $\beta$  in supernatants  
21 after 24 hours as a result of inflammasome activation. As a negative control  
22 for active virus infection, monocytes were stimulated with heat-inactivated  
23 virus (HI-CoV-2) or viral media alone (Mock). First, to evaluate the presence  
24 of replicating virus in SARS-CoV-2-exposed monocyte cultures, we incubated

1 VERO E6 cells, a cell lineage known to be sensitive to SARS-CoV-2 infection,  
2 with SARS-CoV-2-exposed monocyte lysates serially diluted. Although we  
3 failed to detect robust SARS-CoV-2 replication within human monocytes by  
4 using this method (Supplemental Figure 5), SARS-CoV-2 exposure to  
5 monocytes was sufficient to induce IL-1 $\beta$  secretion at MOI of 1, which was not  
6 seen in cultures incubated with HI-CoV-2 at the same MOI or with media only  
7 (mock) (Figure 6A).

8 We then examined the direct role of NLRP3 and ROS generation on  
9 inflammasome activation in response to SARS-CoV-2 in our *in vitro* system,  
10 by incubating monocytes with NLRP3 inhibitor MCC950 or Ferrostatin-1 (Fer-  
11 1), a compound known to inhibit lipid peroxidation. Interestingly, we observed  
12 that live SARS-CoV-2-induced IL-1 $\beta$  production was completely abrogated by  
13 MCC950 and partially inhibited by lipid peroxidation (Figure 6B). These *in vitro*  
14 results suggest that lipid peroxidation, a surrogate of oxidative stress, can  
15 further exacerbate NLRP3-inflammasome activation in response to SARS-  
16 CoV-2.

### 17 **Excessive oxidative stress response and inflammatory profile persist in** 18 **COVID-19 patients after short-term recovery**

19 It has been reported that some COVID-19 patients display lingering  
20 symptoms after disease recovery. This clinical condition known as post-acute  
21 COVID-19 syndrome is not yet well understood and has been described even  
22 in patients who experienced mild disease (Nalbandian et al., 2021; Yong,  
23 2021). Since cell stress and inflammatory measures were elevated in COVID-  
24 19 patients, we sought to investigate whether this exacerbated inflammatory

1 status persisted after a short recovery (approximately 52 days after infection  
2 onset). To do so, we first evaluated the frequency of monocytes along with  
3 expression of phenotypic or inflammatory markers such as CCR2, HLA-DR,  
4 ASC-speck formation, caspase-1 activity, mitochondrial superoxide  
5 generation, lipid peroxidation as well as cytokine production including IL-18,  
6 IL-1 $\beta$ , IL-6 and TNF- $\alpha$  (Figure 7A-L), by comparing those markers across  
7 recovered individuals and HCs. Among all parameters tested, we observed  
8 that CCR2 expression (Figure 7B), FLICA<sup>+</sup>ASC-speck monocyte frequency  
9 (Figure 7D), caspase-1 activity (Figure 7E), lipid peroxidation (Figure 7F),  
10 intracellular GSH levels (Figure 7H) and spontaneous cytokine release *in vitro*  
11 were all significantly altered in the COVID-19 recovered group *versus* HCs,  
12 indicating that short-term recovery does not afford a return to previous levels  
13 for these measurements (Figure 7). In contrast, longitudinal analysis of  
14 revealed a significant increase in CD14<sup>low</sup>CD16<sup>+</sup> monocytes after recovery,  
15 suggesting a restoration of the normal distribution of monocytes subsets in  
16 peripheral blood (Figure 7A). Additionally, measurements associated with  
17 metabolic shift (Supplemental Figure 3C), cell activation (Supplemental Figure  
18 4C-D), inflammasome activation (Supplemental Figure 4E-F), oxidative stress  
19 (Supplemental Figure 4G-H), as well as pro-inflammatory cytokine production  
20 (Supplemental Figure 4I-L) showed no significant difference between the  
21 acute and recovery phase. Importantly, the sustained cellular stress and  
22 inflammatory status found in the COVID-19 patients post-recovery was not  
23 associated with initial disease severity, since this inflammatory profile was  
24 observed regardless of patient classification at the acute phase of the disease  
25 as inpatients (closed symbols) or outpatients (open symbols) (Figure 7 and

1 Supplemental Figure 4). These findings suggest that COVID-19-related stress  
2 and inflammatory responses persist after short-term recovery even in patients  
3 displaying mild symptoms at the acute phase of disease.

4

## 1 DISCUSSION

2 In SARS-CoV-2 infection, inflammatory monocyte-derived  
3 macrophages are the prominent immune cells in the infected lungs, playing a  
4 pivotal role as a major source of inflammatory mediators and thus significantly  
5 contributing to disease progression (Franks et al., 2003; Nicholls et al., 2003).  
6 Herein, we expand this knowledge by showing that approximately 10% of  
7 circulating CD14<sup>high</sup>CD16<sup>-</sup> inflammatory monocytes from COVID-19 patients  
8 demonstrate ASC/Caspase-1/4/5 inflammasome complex formation, which  
9 appears to persist after short-term recovery. These aggregates are required  
10 for caspase-1-mediated IL-1 and IL-18 secretion, highlighting the role of  
11 CD14<sup>high</sup>CD16<sup>-</sup> monocytes in COVID-19 pathogenesis. The enhanced  
12 caspase-1 activity of the pro-inflammatory monocytes strongly correlated with  
13 dysregulated oxidative stress status evidenced by mitochondrial dysfunction,  
14 mitochondrial superoxide generation and lipid peroxidation. Such clinical  
15 findings were confirmed *in vitro*, with oxidative stress identified to be partially  
16 involved in NLRP3-mediated IL-1 $\beta$  secretion by monocyte cultures exposed to  
17 SARS-CoV-2. Importantly, elevated inflammasome activation and aberrant  
18 oxidative stress response were both strongly correlated with worse clinical  
19 disease outcome, supporting the concept that myeloid-derived inflammatory  
20 responses are closely associated with disease severity in COVID-19.

21 Marked phenotypic differences were observed in the monocytic  
22 compartment in COVID-19 patients, including a striking depletion of the  
23 CD14<sup>low</sup>CD16<sup>+</sup> patrolling monocyte subset, an expansion of the  
24 CD14<sup>high</sup>CD16<sup>-</sup> classical/inflammatory monocytes and downmodulation of

1 HLA-DR and CCR2 markers in the CD14<sup>high</sup>CD16<sup>-</sup> cells as reported in other  
2 studies. Robust HLA-DR downregulation in monocytes from COVID-19  
3 hospitalized patients compared to HCs has been previously shown by single-  
4 cell RNA sequencing analysis (Wilk et al., 2020). Dimensionality reduction  
5 analysis of monocytes also indicated a strong phenotypic shift towards the  
6 CD14<sup>+</sup> monocyte subset in patients with acute respiratory distress syndrome  
7 (Wilk et al., 2020). More recently, the SARS-CoV-2 protein ORF7a has been  
8 shown to interact with CD14<sup>+</sup> monocytes, triggering downmodulation of HLA-  
9 DR and production of proinflammatory cytokines *in vitro* (Zhou et al., 2021). It  
10 is not clear, however, whether specific viral factors may also contribute to the  
11 downregulation of CCR2 on classical monocytes. CCR2 expression on  
12 classical CD14<sup>high</sup>CD16<sup>-</sup> monocytes is known to mediate bone marrow egress  
13 and recruitment into inflamed tissues in response to CCL2 (Phillips et al.,  
14 2005). Several studies have shown elevated levels of CCL2 along with other  
15 chemokines in serum and bronchoalveolar fluid (BALF) samples obtained  
16 from COVID-19 patients, which may contribute to classical monocyte  
17 expansion, substantial mononuclear cell infiltration into the lungs, and  
18 consequently tissue damage (Khalil et al., 2021; Merad and Martin, 2020; Wilk  
19 et al., 2020). Thus, our data suggest downmodulation of CCR2 as a possible  
20 compensatory mechanism of CD14<sup>high</sup> monocytes in response to sustained  
21 overproduction of CCL2 or continuous trafficking of CCR2<sup>+</sup> cell into tissues  
22 (Aragay et al., 1998). Intriguingly, our finding showing a failure of CCR2  
23 expression to return to normal levels after short-term recovery indicates  
24 persistent chemokine overexpression and monocyte recruitment even after  
25 the acute phase of the infection.

1           Our results also indicate NLRP3 as the main inflammasome sensor  
2 promoting the poor outcome of COVID-19, in agreement with recently  
3 reported studies (Marchetti et al., 2021; Rodrigues et al., 2021). In this regard,  
4 the presence of NLRP3 inflammasome aggregates has been previously  
5 described in PBMCs and autopsy tissue samples from COVID-19 patients  
6 (Rodrigues et al., 2021; Toldo et al., 2021). Our findings extend these  
7 observations by revealing that aberrant oxidative stress responses evidenced  
8 by mitochondrial superoxide production and lipid peroxidation strongly  
9 associate with caspase-1 activity, suggesting a crosstalk between oxidative  
10 stress and inflammasome activation in SARS-CoV-2 infection. In fact,  
11 intracellular ROS production has been suggested as a key trigger of NLRP3  
12 inflammasome activation as a result of either direct pathogen sensing or in  
13 response to DAMPs released from dying cells (Martinon, 2010; Tschopp and  
14 Schroder, 2010). Previous studies have reported that SARS-CoV  
15 transmembrane pore-forming protein, known as viroporin SARS-CoV 3a or  
16 ORF3a, activates the NLRP3 inflammasome complex in LPS-primed  
17 macrophages through a mechanism dependent on K<sup>+</sup> efflux and  
18 mitochondrial ROS (Chen et al., 2019). In addition, ORF3a was also shown to  
19 promote inflammasome assembly through TRAF3-mediated ubiquitination of  
20 ASC, while another viral protein, ORF8b seems to interact directly with the  
21 leucine-rich repeat domain of NLRP3 to stimulate its activation independent of  
22 ion channel activity (Shi et al., 2019). More recently, an *in vitro* study showed  
23 that SARS-CoV-2 viroporin protein induces the NLRP3-inflammasome  
24 formation in a lung epithelial cell line (Xu et al., 2020), suggesting that SARS-

1 CoV-2 may trigger ROS-mediated NLRP3-inflammasome activation similarly  
2 to SARS-Cov.

3 It remains controversial whether circulating blood monocytes can  
4 express the receptor ACE-2, the dominant entry receptor for SARS-CoV-2,  
5 and thus be actively infected (Gheblawi et al., 2020; Zamorano Cuervo and  
6 Grandvaux, 2020). Although initial work failed to identify ACE-2 on most  
7 tissue-resident macrophages and monocytes (Merad and Martin, 2020), other  
8 studies have shown ACE-2 protein expression in human circulating  
9 monocytes and macrophages by immunoblotting or flow cytometry  
10 (Rutkowska-Zapala et al., 2015; Zhang et al., 2021). More recent reports  
11 suggest that SARS-CoV-2 can actively infect primary human monocytes,  
12 resulting in NLRP3 activation and consequently IL-1 $\beta$  secretion (Ferreira et  
13 al., 2021; Junqueira et al., 2021; Rodrigues et al., 2021). In the present study  
14 we were unable to observe productive infection in human monocytes exposed  
15 to the SARS-CoV-2 virus *in vitro* (Supplemental Figure 5). A possible  
16 explanation for the discrepancy between our results and others relates to the  
17 different approaches used to evaluate SARS-CoV-2-monocyte infection. In  
18 this regard, here we evaluated productive SARS-CoV-2 infection by exposing  
19 VERO E6 indicator cells which are known to be virus susceptible, to monocyte  
20 lysates, whereas other studies have employed rt-PCR or fluorescent-protein  
21 reporter virus to evaluate SARS-CoV-2 infection in human monocyte cultures.

22 Nevertheless, in agreement with a role for direct monocyte sensing of  
23 SARS-CoV-2 in NLRP3 activation, we observed that exposure of primary  
24 human HC monocytes to the active virus was sufficient to promote NLRP3-  
25 driven IL-1 $\beta$  production. Importantly, SARS-CoV-2-induced IL-1 $\beta$  secretion

1 was partially suppressed by treating cells with a lipid peroxidation inhibitor,  
2 Fer-1. This observation is consistent with a recent report showing that  
3 monocyte-derived macrophages and dendritic cells can be activated by  
4 SARS-CoV-2 to induce both cytokine production and cell death even in the  
5 absence of productive infection (Zheng et al., 2021). Our findings, however,  
6 do not rule out the possibility that monocytes/macrophages are able to be  
7 productively infected in patients. In addition to ACE2 binding, other potential  
8 routes of SARS-CoV-2 entry in monocytes have also been proposed such as  
9 binding of the spike protein to the CD147 receptor, antibody-mediated  
10 phagocytosis via Fc gamma receptors, as well as engulfment of dying infected  
11 cells, (Bournazos et al., 2020; Junqueira et al., 2021; Wang et al., 2020).  
12 Nonetheless, further studies with SARS-CoV-2 variants displaying different  
13 mutations are also needed to investigate whether changes in the viral genome  
14 may affect viral uptake by monocytes/macrophages.

15 A major observation of the present study is that the inflammatory  
16 profile of circulating monocytes persists in COVID-19 patients, post-recovery  
17 regardless of their disease severity during acute infection (Figure 7 and  
18 Supplemental Figure 4). It has been reported that about 80% of hospitalized  
19 patients with COVID-19 displayed at least one long-term symptom for several  
20 months after discharge, particularly fatigue and dyspnea (Arnold et al., 2020;  
21 Carfi et al., 2020). Moreover, lingering symptoms and functional impairment  
22 up to eight months after contracting mild SARS-CoV-2 infection was also  
23 reported in a group of low-risk healthcare workers (Havervall et al., 2021).  
24 Indeed, some patients in our cohort, who had experienced either mild or  
25 severe symptoms during acute COVID-19, have also reported the persistence

1 of at least one of the current known COVID-19 symptoms following recovery  
2 from infection. However, we were unable to establish a close association  
3 between the biomarkers tested in this study and any of the residual symptoms  
4 post-recovery. The pathophysiology, risk factors and treatment of post-acute  
5 COVID-19 is currently poorly understood. In that sense, our observations of  
6 sustained dysregulated oxidative stress and inflammasome activation in  
7 monocytes after short-term recovery support the current hypothesis that long  
8 term COVID-19 is driven by persistent pathological inflammation and suggest  
9 the pathways involved as potential targets for therapeutic intervention  
10 (Nalbandian et al., 2021; Yong, 2021). In this regard, it will be important to  
11 evaluate whether persistent immune activation after COVID-19 recovery relies  
12 on the presence of undetectable SARS-CoV-2 virus, viral RNA and/or viral  
13 antigens as well as assess the contribution of unrepairable cellular and tissue  
14 damage.

15 The limitations of the current study include lack of critically ill ventilated  
16 ICU patients (as participants had to be able to provide consent), lack of  
17 multiple longitudinal sampling and small sample size. Nevertheless, our  
18 findings collectively corroborate the hypothesis that early exposure of alveolar  
19 macrophages and endothelial cells to SARS-CoV-2 may induce oxidative  
20 stress dysregulation and aberrant cytokine secretion. This initial cell priming  
21 event may contribute to the enhanced recruitment to the site of infection of  
22 pre-activated circulating monocytes pre-committed to inflammasome  
23 activation and aberrant oxidative stress response, resulting in exacerbation of  
24 tissue immunopathology and ultimately organ failure. In this context, recent  
25 advances in targeting ROS by administration of glutathione or glutathione

1 precursors (N-acetyl-cysteine, NAC), as well as IL-1 signaling by  
2 administrating Anakinra, a IL-1 Receptor antagonist (IL-1Ra), have been  
3 reported to prevent inflammation and/or worse clinical outcome in COVID-19  
4 patients (Cauchois et al., 2020; Cavalli et al., 2020; Horowitz et al., 2020;  
5 Huet et al., 2020; Ibrahim et al., 2020; Kyriazopoulou et al., 2021a;  
6 Kyriazopoulou et al., 2021b). Thus, our findings suggest that early treatment  
7 with antioxidants and IL-1 signaling inhibitors may represent potential  
8 therapeutic intervention for COVID-19 by preventing deleterious effects  
9 downstream of the inflammasome pathway and consequently tissue  
10 immunopathology and that such interventions may have a role in the recovery  
11 phase of the disease.

## 1 **Materials and methods**

### 2 **Plasma biomarker measurements**

3 Cryopreserved plasma samples from HCs and patients were assessed to  
4 measure levels of the following inflammatory biomarkers according to the  
5 manufacturer's instructions. Levels of IFN- $\gamma$ , IL-2, IL-6, IL-7, IL-8, IL-10, IL-  
6 12p70, TNF- $\alpha$ , IL-27, E-Selectin, P-Selectin, ICAM-3, SAA, CRP, VCAM-1,  
7 ICAM-1 and IL-18 were quantified using electrochemiluminescence kits from  
8 Meso SCALE (Gaithersburg, MD, USA). Levels of ferritin heavy chain (ferritin-  
9 H) were determined by enzyme-linked immunosorbent assay (ELISA) from  
10 Thermo Fisher Scientific (Rockford, IL, USA). D-dimer levels were measured  
11 using Enzyme Linked Fluorescence Antibody kits from BioMerieux, MA, USA.  
12 Levels of iron was assessed using a commercial kit from Novus Biologicals  
13 (Centennial, CO). Concentrations of catalase, superoxide dismutase activity  
14 (SOD) and total oxidant status were measured using kits from Sigma-Aldrich  
15 (St. Louis, MO, USA). Levels of sCD14 and sIL-6Ra were quantified by ELISA  
16 from R&D Systems (Minneapolis, MN, USA). Lipid peroxidation in plasma was  
17 assessed using an assay kit from Cayman Chemical, which measures the  
18 formation of malondialdehyde (MDA).

### 19 **Cell culture and treatments**

20 Cryopreserved ficoll-isolated peripheral blood mononuclear cells (PBMCs)  
21 from patients or healthy control individuals (HCs) were thawed and  
22 resuspended in RPMI-1640 media (Corning, NY, USA) supplemented with  
23 10% heat-inactivated human AB serum (Gemini Bio-Products, West

1 Sacramento, USA) and 0.05% benzonase (MilliporeSigma, USA). Cells were  
2 rested for 1 hour at 37 °C and 5% CO<sub>2</sub> and subsequently plated at 10<sup>6</sup>  
3 cells/well in round bottom 96-well plates (Corning Costar™, MilliporeSigma,  
4 USA) followed by immune staining. Alternatively, cells were incubated for 3hr,  
5 in the presence or absence of MCC950 (3 μM; Invivogen, CA, USA) or  
6 colchicine (10 μM; Sigma-Aldrich, St Louis, MO, USA) for inflammasome  
7 inhibition. IL-1β, IL-6 and TNF-α were quantified in culture supernatants by  
8 using Multi-Analyte Flow Assay Kit (LEGENDplex) from Biolegend, following  
9 the manufacturer's instructions.

## 10 **Inflammasome and mitochondrial status assessment by Imaging Flow** 11 **Cytometry**

12 Inflammasome complex assembly was evaluated by detection of ASC speck  
13 formation by imaging flow cytometry, as previously described (Lage et al.,  
14 2019). Briefly, PBMCs were incubated with the fluorochrome inhibitor of  
15 caspase-1/4/5 (FAM-FLICA, Immunochemistry technologies (ICT),  
16 Bloomington, MN) following the manufacturer's instructions, for 50 min at  
17 37 °C, to allow for binding of FLICA to activated inflammatory caspases. Cells  
18 were washed twice with the FLICA kit wash buffer and then incubated with  
19 LIVE/DEAD Fixable AQUA Dead Cells Stain (Thermo Fisher, USA) for 15 min  
20 at RT, followed by extracellular staining in PBS + 1% BSA with the following  
21 fluorochrome-conjugated antibodies for monocyte phenotyping: anti-CD14  
22 BV605 (Clone:M5E2), anti-CD16 PE-Cy7 (Clone:3G8), and anti-CD3 PE  
23 (Clone:HIT3a) from BioLegend, San Diego, CA, USA; anti-CD20 PE  
24 (Clone:2H7), anti-CD19 PE (Clone:SJ25C1), anti-CD2 PE (Clone:RPA-2.10),

1 from eBioscience, San Diego, CA; anti-CD56 PE [(Clone: B159 (RUO))], anti-  
2 HLA-DR BV421 [Clone: G46-6 (RUO)] and anti-CD66b (Clone:G10F5) from  
3 BD Biosciences, Franklin Lakes, New Jersey. Cells were fixed and  
4 permeabilized with Cytofix/Cytoperm (BD Biosciences, USA) overnight at 4°C  
5 and stained for 1h at RT for intracellular ASC, with anti-ASC/TMS1 AF647  
6 antibody from Novus Biologicals, Littleton, CO. In parallel, cells were stained  
7 with monocyte markers and 200 nM Mitotracker Red (MitoTracker™ Red  
8 CMXRos, Invitrogen) followed by ASC intracellular staining for mitochondrial  
9 membrane potential evaluation. Cells were acquired using a 12-channel  
10 Amnis ImageStreamX Mark II (MilliporeSigma) imaging flow cytometer and  
11 the integrated software INSPIRE (MilliporeSigma) was used for data  
12 collection. Images were analyzed using image-based algorithms in the  
13 ImageStream Data Exploration and Analysis Software (IDEAS 6.2.64.0,  
14 MilliporeSigma) as described previously (Lage et al., 2019).

## 15 **Flow Cytometry**

16 PBMCs were stained with the following list of fluorescently labeled antibodies  
17 against cell surface markers subsequently detected by flow cytometry: anti-  
18 CD14 BV605 (Clone:M5E2), anti-CD16 PE-Cy7/BV711 (Clone:3G8), and anti-  
19 CD3 PE (Clone:HIT3a) from BioLegend; anti-CD20 e450 (Clone:2H7), anti-  
20 CD19 e450 (Clone:SJ25C1), anti-CD2 e450 (Clone:RPA-2.10), from  
21 eBioscience; anti-CD56 e450 [(Clone: B159 (RUO))], anti-HLA-DR APC-Cy7  
22 [Clone: G46-6 (RUO)] and anti-CD66b e450 (Clone:G10F5) and CCR2 PerCP  
23 Cy5.5 [Clone:] from BD Biosciences. Staining protocol proceeded as  
24 described above for imaging flow cytometry analysis. Surface Glut-1 receptor

1 expression was detected by binding to the Glut-1 ligand fused to enhanced  
2 green fluorescent protein (GFP) (Metafora Biosystems, Evry, France), as  
3 previously described (Hammoud et al., 2019). In brief,  $10^6$  cells were  
4 incubated for 20 minutes with 10  $\mu$ L of Glut-1–GFP solution prior to Live/Dead  
5 staining using LIVE/DEAD Cell Viability Assay (Life Technologies, CA, USA).  
6 GFP fluorescence was detected by staining cells with Alexa Fluor 647 anti-  
7 GFP antibody at 1:200 (Biolegend). Data were acquired on a BD Fortessa  
8 flow cytometer (BD Biosciences). All compensation and gating analyses were  
9 performed using FlowJo 10.5.3 (TreeStar, Ashland, OR, USA).

## 10 **Lipid peroxidation assay**

11 Lipid peroxidation in total PBMC cultures was assessed by using the Click-iT  
12 Lipid Peroxidation Imaging Kit (Life Technologies, SA, USA) according to the  
13 manufacturer's instructions. Cells were incubated with the LAA reagent  
14 (alkyne-modified linoleic acid) for detection of lipid peroxidation-derived  
15 protein modifications at 37°C for 1 h, and then washed with 1 $\times$  DPBS. After  
16 cell centrifugation (1,500 rpm for 5 min) to remove the LAA reagent, cells  
17 were incubated with antibodies to measure lipid peroxidation only in CD14+  
18 monocytes. Live/Dead staining was performed as described previously above  
19 and the cells fixed by adding cytofix/cytoperm (BD bioscience, USA). After  
20 completing the LAA staining, fixed cells were washed, and resuspended in 1 $\times$   
21 DPBS, and then LAA fluorescence was analyzed by flow cytometry.

## 1 **Measurement of intracellular GSH levels**

2 Intracellular GSH levels were measured in PBMC lysates by using a  
3 Glutathione Assay Kit (Cayman Chemical, USA) according to the  
4 manufacturer's instructions. Total GSH levels were normalized by total protein  
5 concentration determined by using a Pierce BCA protein Assay kit (Thermo  
6 Fisher, IL, USA).

## 7 **Mitochondrial superoxide assay**

8 Mitochondrial superoxide was detected by using a flow cytometry–based  
9 assay. Total PBMCs were washed with Hank's balanced salt solution with  
10 calcium and magnesium (HBSS/Ca/Mg, Gibco, USA) to remove residual  
11 media by centrifugation. Cell pellet was stained with MitoSOX probe (Life  
12 Technologies, USA) at 37°C for 30 min following the manufacturer's protocol.  
13 Cells were next washed with HBSS/Ca/Mg and incubated with antibodies to  
14 analyze CD14<sup>+</sup> monocytes by flow cytometry. Cells fixed with 2%  
15 paraformaldehyde at room temperature for 30 min. Fluorescence intensity of  
16 the probe was then measured by flow cytometric analysis.

## 17 ***In vitro* exposure of human monocytes to SARS-CoV-2**

18 Elutriated monocytes isolated from fresh PBMCs were co-cultured with SARS-  
19 CoV-2 USA-WA1/2020 at different MOIs for 3 hours at 37°C under low serum  
20 conditions (2% fetal calf serum) in a Biosafety Level 3 facility. Control cells  
21 were co-cultured with heat-inactivated SARS-CoV-2 USA-WA1/2020 at a MOI  
22 of 1, mock viral supernatant at a MOI of 1 or media alone. After 3 hours of  
23 viral exposure, monocytes were treated with Ferrostatin-1 (Fer-1) (10µM;

1 Selleck, USA), MCC950 (10 $\mu$ M; Invivogen, CA, USA) or vehicle (DMSO;  
2 Sigma-Aldrich, St. Louis, MO, USA) and thus incubated for an additional 21  
3 hours at 37°C. Cell supernatants were harvested for quantification of IL-1 $\beta$  by  
4 ELISA following the manufacturer's directions (Sigma-Aldrich, USA).

5 To determine viral titers by TCID<sub>50</sub> assay, cells were harvested, lysed by  
6 freeze/thawing and plated in triplicate onto Vero E6 cells using 10-fold serial  
7 dilutions. Viral stock was used as a positive control. Plates were stained with  
8 crystal violet after 96 hours to assess CPE. Viral titers were determined using  
9 the Reed-Muench method.

## 10 **Statistical Analyses**

11 Statistical analyses were performed using non-parametric Mann-Whitney or  
12 Kruskal-Wallis test in GraphPad Prism 8.0.1 software (GraphPad, USA). Data  
13 are presented as median with interquartile ranges. Spearman's correlation  
14 analyses were performed using R. Differences between groups or parameters  
15 were considered significant when  $p \leq 0.05$ .

## 16 **Study participants and approval**

17 Study participants were enrolled in the NIH clinical protocol: COVID-19-  
18 associated Lymphopenia Pathogenesis Study in Blood (CALYPSO),  
19 NCT04401436, which recruited at the NIH clinical center, Washington  
20 Hospital Center and Georgetown University Hospital. Healthy volunteer blood  
21 samples were obtained under the protocol 99-CC-0168 and were de-identified  
22 prior to distribution. Protocols in this study were reviewed and approved by  
23 the National Institutes of Health (NIH) Central Intramural Institutional Review

1 Board (IRB). All participants provided written informed consent prior to any  
2 study procedures in accordance with the Declaration of Helsinki. Patients  
3 enrolled in this study were classified according to their highest oxygen  
4 requirement up until the time of the research blood draw in (1) mild cases, in  
5 which patients required 4 Liters or less, (2) moderate cases, when their  
6 requirement was up to 50% oxygen concentration (FiO<sub>2</sub>), and (3) severe  
7 cases, in which patients required over 50% FiO<sub>2</sub> or ICU care. Only patients  
8 who were able to consent themselves were eligible to participate, which  
9 limited the enrollment of critically ill ventilated ICU patients. In addition, 14  
10 patients were sampled longitudinally, at the acute phase of the disease and  
11 after a short-term recovery period (approximately 52 days after infection  
12 onset) and 2 patients were enrolled after their recovery.

### 13 **AUTHOR CONTRIBUTIONS**

14 SLL, EPA, AS and IS were involved in conception and design of the study and  
15 experiments. SLL, EPA, KH, AR, SN and JR performed experiments and/or  
16 data analysis. EL, PK, GW, RP, FG, AK, JR, MM, AL and IS recruited  
17 patients, assisted in clinical care and helped with data curation and/or  
18 visualization. AR, AS, IS, JPS and HDH provided resources and reagents.  
19 SLL, EPA and IS were involved in drafting the manuscript. All authors have  
20 reviewed and approved the final manuscript.

### 21 **ACKNOWLEDGMENTS**

22 This project was supported in part by the intramural research program of  
23 NIAID/NIH, with federal funds from the National Cancer Institute, National

1 Institutes of Health, under Contract No. HHSN261200800001E. KH was  
2 supported by a Malahan Institute Postdoctoral Fellowship. The content of this  
3 publication does not necessarily reflect the views or policies of the  
4 Department of Health and Human Services, nor does mention of trade names,  
5 commercial products, or organizations imply endorsement by the U.S.  
6 Government. The authors declare no competing financial interests. We are  
7 grateful to the patients enrolled in protocols and blood bank healthy donors for  
8 making this study possible. We also thank Drs Kumar and Woltmann and their  
9 associated staff at WHC and Georgetown, as well as the OP8 Infectious  
10 Diseases Clinic staff for their assistance in patient recruitment and evaluation.  
11 We also thank David Stephany for his technical support.

12

## 13 REFERENCES

14

- 15 Abais, J.M., M. Xia, Y. Zhang, K.M. Boini, and P.L. Li. 2015. Redox regulation of  
16 NLRP3 inflammasomes: ROS as trigger or effector? *Antioxid Redox Signal*  
17 22:1111-1129.
- 18 Ackermann, M., S.E. Verleden, M. Kuehnel, A. Haverich, T. Welte, F. Laenger, A.  
19 Vanstapel, C. Werlein, H. Stark, A. Tzankov, W.W. Li, V.W. Li, S.J. Mentzer,  
20 and D. Jonigk. 2020. Pulmonary Vascular Endothelialitis, Thrombosis, and  
21 Angiogenesis in Covid-19. *N Engl J Med* 383:120-128.
- 22 Agbuduwe, C., and S. Basu. 2020. Haematological manifestations of COVID-19:  
23 From cytopenia to coagulopathy. *Eur J Haematol* 105:540-546.
- 24 Amaral, E.P., C.L. Vinhaes, D. Oliveira-de-Souza, B. Nogueira, K.M. Akrami, and  
25 B.B. Andrade. 2021. The Interplay Between Systemic Inflammation,  
26 Oxidative Stress, and Tissue Remodeling in Tuberculosis. *Antioxid Redox*  
27 *Signal* 34:471-485.
- 28 Angajala, A., S. Lim, J.B. Phillips, J.H. Kim, C. Yates, Z. You, and M. Tan. 2018.  
29 Diverse Roles of Mitochondria in Immune Responses: Novel Insights Into  
30 Immuno-Metabolism. *Front Immunol* 9:1605.
- 31 Aragay, A.M., M. Mellado, J.M. Frade, A.M. Martin, M.C. Jimenez-Sainz, A.C.  
32 Martinez, and F. Mayor, Jr. 1998. Monocyte chemoattractant protein-1-

- 1 induced CCR2B receptor desensitization mediated by the G protein-  
2 coupled receptor kinase 2. *Proc Natl Acad Sci U S A* 95:2985-2990.
- 3 Arnold, D.T., F.W. Hamilton, A. Milne, A.J. Morley, J. Viner, M. Attwood, A. Noel, S.  
4 Gunning, J. Hatrick, S. Hamilton, K.T. Elvers, C. Hyams, A. Bibby, E. Moran,  
5 H.I. Adamali, J.W. Dodd, N.A. Maskell, and S.L. Barratt. 2020. Patient  
6 outcomes after hospitalisation with COVID-19 and implications for  
7 follow-up: results from a prospective UK cohort. *Thorax*
- 8 Balendiran, G.K., R. Dabur, and D. Fraser. 2004. The role of glutathione in cancer.  
9 *Cell Biochem Funct* 22:343-352.
- 10 Bhat, S.A., N. Singh, A. Trivedi, P. Kansal, P. Gupta, and A. Kumar. 2012. The  
11 mechanism of redox sensing in Mycobacterium tuberculosis. *Free Radic*  
12 *Biol Med* 53:1625-1641.
- 13 Biemond, P., A.J. Swaak, C.M. Beindorff, and J.F. Koster. 1986. Superoxide-  
14 dependent and -independent mechanisms of iron mobilization from  
15 ferritin by xanthine oxidase. Implications for oxygen-free-radical-induced  
16 tissue destruction during ischaemia and inflammation. *Biochem J*  
17 239:169-173.
- 18 Biemond, P., H.G. van Eijk, A.J. Swaak, and J.F. Koster. 1984. Iron mobilization  
19 from ferritin by superoxide derived from stimulated polymorphonuclear  
20 leukocytes. Possible mechanism in inflammation diseases. *J Clin Invest*  
21 73:1576-1579.
- 22 Bonaventura, A., A. Vecchie, L. Dagna, K. Martinod, D.L. Dixon, B.W. Van Tassell, F.  
23 Dentali, F. Montecucco, S. Massberg, M. Levi, and A. Abbate. 2021.  
24 Endothelial dysfunction and immunothrombosis as key pathogenic  
25 mechanisms in COVID-19. *Nat Rev Immunol* 21:319-329.
- 26 Bou-Abdallah, F., J.J. Paliakkara, G. Melman, and A. Melman. 2018. Reductive  
27 Mobilization of Iron from Intact Ferritin: Mechanisms and Physiological  
28 Implication. *Pharmaceuticals (Basel)* 11:
- 29 Bournazos, S., A. Gupta, and J.V. Ravetch. 2020. The role of IgG Fc receptors in  
30 antibody-dependent enhancement. *Nat Rev Immunol* 20:633-643.
- 31 Broz, P., J. von Moltke, J.W. Jones, R.E. Vance, and D.M. Monack. 2010. Differential  
32 requirement for Caspase-1 autoproteolysis in pathogen-induced cell  
33 death and cytokine processing. *Cell Host Microbe* 8:471-483.
- 34 Burgunder, J.M., and B.H. Lauterburg. 1987. Decreased production of glutathione  
35 in patients with cirrhosis. *Eur J Clin Invest* 17:408-414.
- 36 Carfi, A., R. Bernabei, F. Landi, and C.-P.-A.C.S.G. Gemelli Against. 2020. Persistent  
37 Symptoms in Patients After Acute COVID-19. *JAMA* 324:603-605.
- 38 Cauchois, R., M. Koubi, D. Delarbre, C. Manet, J. Carvelli, V.B. Blasco, R. Jean, L.  
39 Fouche, C. Bornet, V. Pauly, K. Mazodier, V. Pestre, P.A. Jarrot, C.A.  
40 Dinarello, and G. Kaplanski. 2020. Early IL-1 receptor blockade in severe  
41 inflammatory respiratory failure complicating COVID-19. *Proc Natl Acad*  
42 *Sci U S A* 117:18951-18953.
- 43 Cavalca, V., F. Veglia, I. Squellerio, G. Marenzi, F. Minardi, M. De Metrio, G.  
44 Cighetti, L. Boccotti, P. Ravagnani, and E. Tremoli. 2009. Glutathione,  
45 vitamin E and oxidative stress in coronary artery disease: relevance of age  
46 and gender. *Eur J Clin Invest* 39:267-272.
- 47 Cavalli, G., G. De Luca, C. Campochiaro, E. Della-Torre, M. Ripa, D. Canetti, C.  
48 Oltolini, B. Castiglioni, C. Tassan Din, N. Boffini, A. Tomelleri, N. Farina, A.  
49 Ruggeri, P. Rovere-Querini, G. Di Lucca, S. Martinenghi, R. Scotti, M.

- 1           Tresoldi, F. Ciceri, G. Landoni, A. Zangrillo, P. Scarpellini, and L. Dagna.  
2           2020. Interleukin-1 blockade with high-dose anakinra in patients with  
3           COVID-19, acute respiratory distress syndrome, and hyperinflammation:  
4           a retrospective cohort study. *Lancet Rheumatol* 2:e325-e331.
- 5           Chaves, F.J., M.L. Mansego, S. Blesa, V. Gonzalez-Albert, J. Jimenez, M.C. Tormos, O.  
6           Espinosa, V. Giner, A. Iradi, G. Saez, and J. Redon. 2007. Inadequate  
7           cytoplasmic antioxidant enzymes response contributes to the oxidative  
8           stress in human hypertension. *Am J Hypertens* 20:62-69.
- 9           Chen, I.Y., M. Moriyama, M.F. Chang, and T. Ichinohe. 2019. Severe Acute  
10          Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3  
11          Inflammasome. *Front Microbiol* 10:50.
- 12          Conti, P., G. Ronconi, A. Caraffa, C.E. Gallenga, R. Ross, I. Frydas, and S.K. Kritas.  
13          2020. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung  
14          inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-  
15          inflammatory strategies. *J Biol Regul Homeost Agents* 34:327-331.
- 16          Dandel, M. 2021. Pathophysiology of COVID-19-associated acute respiratory  
17          distress syndrome. *Lancet Respir Med* 9:e4.
- 18          Delgado-Roche, L., and F. Mesta. 2020. Oxidative Stress as Key Player in Severe  
19          Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection. *Arch Med*  
20          *Res* 51:384-387.
- 21          Erlich, J.R., E.E. To, S. Liong, R. Brooks, R. Vlahos, J.J. O'Leary, D.A. Brooks, and S.  
22          Selemidis. 2020. Targeting Evolutionary Conserved Oxidative Stress and  
23          Immunometabolic Pathways for the Treatment of Respiratory Infectious  
24          Diseases. *Antioxid Redox Signal* 32:993-1013.
- 25          Fakhri, S., Z. Nouri, S.Z. Moradi, and M.H. Farzaei. 2020. Astaxanthin, COVID-19  
26          and immune response: Focus on oxidative stress, apoptosis and  
27          autophagy. *Phytother Res* 34:2790-2792.
- 28          Favier, A., C. Sappey, P. Leclerc, P. Faure, and M. Micoud. 1994. Antioxidant status  
29          and lipid peroxidation in patients infected with HIV. *Chem Biol Interact*  
30          91:165-180.
- 31          Ferreira, A.C., V.C. Soares, I.G. de Azevedo-Quintanilha, S. Dias, N. Fintelman-  
32          Rodrigues, C.Q. Sacramento, M. Mattos, C.S. de Freitas, J.R. Temerozo, L.  
33          Teixeira, E. Damaceno Hottz, E.A. Barreto, C.R.R. Pao, L. Palhinha, M.  
34          Miranda, D.C. Bou-Habib, F.A. Bozza, P.T. Bozza, and T.M.L. Souza. 2021.  
35          SARS-CoV-2 engages inflammasome and pyroptosis in human primary  
36          monocytes. *Cell Death Discov* 7:43.
- 37          Fitzpatrick, A.M., D.P. Jones, and L.A. Brown. 2012. Glutathione redox control of  
38          asthma: from molecular mechanisms to therapeutic opportunities.  
39          *Antioxid Redox Signal* 17:375-408.
- 40          Fitzpatrick, A.M., W.G. Teague, L. Burwell, M.S. Brown, L.A. Brown, and N.N.S.A.R.  
41          Program. 2011. Glutathione oxidation is associated with airway  
42          macrophage functional impairment in children with severe asthma.  
43          *Pediatr Res* 69:154-159.
- 44          Fitzpatrick, A.M., W.G. Teague, F. Holguin, M. Yeh, L.A. Brown, and P. Severe  
45          Asthma Research. 2009. Airway glutathione homeostasis is altered in  
46          children with severe asthma: evidence for oxidant stress. *J Allergy Clin*  
47          *Immunol* 123:146-152 e148.
- 48          Franks, T.J., P.Y. Chong, P. Chui, J.R. Galvin, R.M. Lourens, A.H. Reid, E. Selbs, C.P.  
49          McEvoy, C.D. Hayden, J. Fukuoka, J.K. Taubenberger, and W.D. Travis.

- 1           2003. Lung pathology of severe acute respiratory syndrome (SARS): a  
2           study of 8 autopsy cases from Singapore. *Hum Pathol* 34:743-748.
- 3   Freeborn, R.A., and C.E. Rockwell. 2021. The role of Nrf2 in autoimmunity and  
4           infectious disease: Therapeutic possibilities. *Adv Pharmacol* 91:61-110.
- 5   Freeman, T.L., and T.H. Swartz. 2020. Targeting the NLRP3 Inflammasome in  
6           Severe COVID-19. *Front Immunol* 11:1518.
- 7   Gheblawi, M., K. Wang, A. Viveiros, Q. Nguyen, J.C. Zhong, A.J. Turner, M.K.  
8           Raizada, M.B. Grant, and G.Y. Oudit. 2020. Angiotensin-Converting  
9           Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin  
10          System: Celebrating the 20th Anniversary of the Discovery of ACE2. *Circ*  
11          *Res* 126:1456-1474.
- 12   Gibson, P.G., L. Qin, and S.H. Puah. 2020. COVID-19 acute respiratory distress  
13          syndrome (ARDS): clinical features and differences from typical pre-  
14          COVID-19 ARDS. *Med J Aust* 213:54-56 e51.
- 15   Goutzourelas, N., M. Orfanou, I. Charizanis, G. Leon, D.A. Spandidos, and D.  
16          Kouretas. 2018. GSH levels affect weight loss in individuals with  
17          metabolic syndrome and obesity following dietary therapy. *Exp Ther Med*  
18          16:635-642.
- 19   Hammoud, D.A., A. Boulougoura, G.Z. Papadakis, J. Wang, L.E. Dodd, A. Rupert, J.  
20          Higgins, G. Roby, D. Metzger, E. Laidlaw, J.M. Mican, A. Pau, S. Lage, C.S.  
21          Wong, A. Lisco, M. Manion, V. Sheikh, C. Millo, and I. Sereti. 2019.  
22          Increased Metabolic Activity on 18F-Fluorodeoxyglucose Positron  
23          Emission Tomography-Computed Tomography in Human  
24          Immunodeficiency Virus-Associated Immune Reconstitution  
25          Inflammatory Syndrome. *Clin Infect Dis* 68:229-238.
- 26   Havervall, S., A. Rosell, M. Phillipson, S.M. Mangsbo, P. Nilsson, S. Hober, and C.  
27          Thalin. 2021. Symptoms and Functional Impairment Assessed 8 Months  
28          After Mild COVID-19 Among Health Care Workers. *JAMA* 325:2015-2016.
- 29   Hojyo, S., M. Uchida, K. Tanaka, R. Hasebe, Y. Tanaka, M. Murakami, and T. Hirano.  
30          2020. How COVID-19 induces cytokine storm with high mortality.  
31          *Inflamm Regen* 40:37.
- 32   Horby, P.W., M. Campbell, E. Spata, J.R. Emberson, N. Staplin, G. Pessoa-Amorim,  
33          L. Peto, M. Wiselka, L. Wiffen, S. Tiberi, B. Caplin, C. Wroe, C. Green, P.  
34          Hine, B. Prudon, T. George, A. Wight, J.K. Baillie, B. Basnyat, M.H. Buch, L.C.  
35          Chappell, J.N. Day, S.N. Faust, R.L. Hamers, T. Jaki, E. Juszczak, K. Jeffery,  
36          W.S. Lim, A. Montgomery, A. Mumford, K. Rowan, G. Thwaites, M. Mafham,  
37          R. Haynes, and M.J. Landray. 2021. Colchicine in patients admitted to  
38          hospital with COVID-19 (RECOVERY): a randomised, controlled, open-  
39          label, platform trial. *medRxiv* 2021.2005.2018.21257267.
- 40   Hornung, V., F. Bauernfeind, A. Halle, E.O. Samstad, H. Kono, K.L. Rock, K.A.  
41          Fitzgerald, and E. Latz. 2008. Silica crystals and aluminum salts activate  
42          the NALP3 inflammasome through phagosomal destabilization. *Nat*  
43          *Immunol* 9:847-856.
- 44   Horowitz, R.I., P.R. Freeman, and J. Bruzzese. 2020. Efficacy of glutathione  
45          therapy in relieving dyspnea associated with COVID-19 pneumonia: A  
46          report of 2 cases. *Respir Med Case Rep* 30:101063.
- 47   Huet, T., H. Beaussier, O. Voisin, S. Jouveshomme, G. Dauriat, I. Lazareth, E. Sacco,  
48          J.M. Naccache, Y. Bezie, S. Laplanche, A. Le Berre, J. Le Pavec, S. Salmeron,

- 1 J. Emmerich, J.J. Mourad, G. Chatellier, and G. Hayem. 2020. Anakinra for  
2 severe forms of COVID-19: a cohort study. *Lancet Rheumatol* 2:e393-e400.
- 3 Ibrahim, H., A. Perl, D. Smith, T. Lewis, Z. Kon, R. Goldenberg, K. Yarta, C.  
4 Staniloae, and M. Williams. 2020. Therapeutic blockade of inflammation  
5 in severe COVID-19 infection with intravenous N-acetylcysteine. *Clin*  
6 *Immunol* 219:108544.
- 7 Iyer, S.S., Q. He, J.R. Janczy, E.I. Elliott, Z. Zhong, A.K. Olivier, J.J. Sadler, V.  
8 Knepper-Adrian, R. Han, L. Qiao, S.C. Eisenbarth, W.M. Nauseef, S.L. Cassel,  
9 and F.S. Sutterwala. 2013. Mitochondrial cardiolipin is required for Nlrp3  
10 inflammasome activation. *Immunity* 39:311-323.
- 11 Junqueira, C., A. Crespo, S. Ranjbar, J. Ingber, B. Parry, S. Ravid, L.B. de Lacerda, M.  
12 Lewandrowski, S. Clark, F. Ho, S.M. Vora, V. Leger, C. Beakes, J. Margolin,  
13 N. Russell, L. Gehrke, U.D. Adhikari, L. Henderson, E. Janssen, D. Kwon, C.  
14 Sander, J. Abraham, M. Filbin, M.B. Goldberg, H. Wu, G. Mehta, S. Bell, A.E.  
15 Goldfeld, and J. Lieberman. 2021. SARS-CoV-2 infects blood monocytes to  
16 activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine  
17 release. *medRxiv*
- 18 Khalil, B.A., N.M. Elemam, and A.A. Maghazachi. 2021. Chemokines and  
19 chemokine receptors during COVID-19 infection. *Comput Struct*  
20 *Biotechnol J* 19:976-988.
- 21 Kyriazopoulou, E., P. Panagopoulos, S. Metallidis, G.N. Dalekos, G. Poulakou, N.  
22 Gatselis, E. Karakike, M. Saridaki, G. Loli, A. Stefos, D. Prasianaki, S.  
23 Georgiadou, O. Tsachouridou, V. Petrakis, K. Tsiakos, M. Kosmidou, V.  
24 Lygoura, M. Dareioti, H. Millionis, I.C. Papanikolaou, K. Akinosoglou, D.M.  
25 Myrodia, A. Gravvani, A. Stamou, T. Gkavogianni, K. Katrini, T. Marantos,  
26 I.P. Trontzas, K. Syrigos, L. Chatzis, S. Chatzis, N. Vechlidis, C. Avgoustou, S.  
27 Chalvatzis, M. Kyprianou, J.W. van der Meer, J. Eugen-Olsen, M.G. Netea,  
28 and E.J. Giamarellos-Bourboulis. 2021a. An open label trial of anakinra to  
29 prevent respiratory failure in COVID-19. *Elife* 10:
- 30 Kyriazopoulou, E., G. Poulakou, H. Millionis, S. Metallidis, G. Adamis, K. Tsiakos, A.  
31 Fragkou, A. Rapti, C. Damoulari, M. Fantoni, I. Kalomenidis, G. Chrysos, A.  
32 Angheben, I. Kainis, Z. Alexiou, F. Castelli, F.S. Serino, M. Tsilika, P.  
33 Bakakos, E. Nicastri, V. Tzavara, E. Kostis, L. Dagna, P. Koufargyris, K.  
34 Dimakou, S. Savvanis, G. Tzatzagou, M. Chini, G. Cavalli, M. Bassetti, K.  
35 Katrini, V. Kotsis, G. Tsoukalas, C. Selmi, I. Bliziotis, M. Samarkos, M.  
36 Doulmas, S. Ktena, A. Masgala, I. Papanikolaou, M. Kosmidou, D.M.  
37 Myrodia, A. Argyraki, C.S. Cardellino, K. Koliakou, E.I. Katsigianni, V. Rapti,  
38 E. Giannitsioti, A. Cingolani, S. Micha, K. Akinosoglou, O. Liatsis-Douvitsas,  
39 S. Symbardi, N. Gatselis, M. Mouktaroudi, G. Ippolito, E. Florou, A. Kotsaki,  
40 M.G. Netea, J. Eugen-Olsen, M. Kyprianou, P. Panagopoulos, G.N. Dalekos,  
41 and E.J. Giamarellos-Bourboulis. 2021b. Early treatment of COVID-19 with  
42 anakinra guided by soluble urokinase plasminogen receptor plasma  
43 levels: a double-blind, randomized controlled phase 3 trial. *Nat Med*
- 44 Lage, S.L., V.M. Dominical, C.S. Wong, and I. Sereti. 2019. Evaluation of Canonical  
45 Inflammasome Activation in Human Monocytes by Imaging Flow  
46 Cytometry. *Front Immunol* 10:1284.
- 47 Lopes, M.I., L.P. Bonjorno, M.C. Giannini, N.B. Amaral, P.I. Menezes, S.M. Dib, S.L.  
48 Gigante, M.N. Benatti, U.C. Rezek, L.L. Emrich-Filho, B.A.A. Sousa, S.C.L.  
49 Almeida, R. Luppino Assad, F.P. Veras, A. Schneider, T.S. Rodrigues, L.O.S.

- 1 Leiria, L.D. Cunha, J.C. Alves-Filho, T.M. Cunha, E. Arruda, C.H. Miranda, A.  
2 Pazin-Filho, M. Auxiliadora-Martins, M.C. Borges, B.A.L. Fonseca, V.R.  
3 Bollela, C.M. Del-Ben, F.Q. Cunha, D.S. Zamboni, R.C. Santana, F.C. Vilar, P.  
4 Louzada-Junior, and R.D.R. Oliveira. 2021. Beneficial effects of colchicine  
5 for moderate to severe COVID-19: a randomised, double-blinded, placebo-  
6 controlled clinical trial. *RMD Open* 7:  
7 Lu, A., V.G. Magupalli, J. Ruan, Q. Yin, M.K. Atianand, M.R. Vos, G.F. Schroder, K.A.  
8 Fitzgerald, H. Wu, and E.H. Egelman. 2014. Unified polymerization  
9 mechanism for the assembly of ASC-dependent inflammasomes. *Cell*  
10 156:1193-1206.  
11 Lutchmansingh, F.K., J.W. Hsu, F.I. Bennett, A.V. Badaloo, N. McFarlane-Anderson,  
12 G.M. Gordon-Strachan, R.A. Wright-Pascoe, F. Jahoor, and M.S. Boyne.  
13 2018. Glutathione metabolism in type 2 diabetes and its relationship with  
14 microvascular complications and glycemia. *PLoS One* 13:e0198626.  
15 Marchetti, C., K. Mould, I.W. Tengesdal, W.J. Janssen, and C.A. Dinarello. 2021.  
16 Targeting of the NLRP3 Inflammasome for early COVID-19. *bioRxiv*  
17 2021.2002.2024.432734.  
18 Martinon, F. 2010. Signaling by ROS drives inflammasome activation. *Eur J*  
19 *Immunol* 40:616-619.  
20 Martinon, F., K. Burns, and J. Tschopp. 2002. The inflammasome: a molecular  
21 platform triggering activation of inflammatory caspases and processing of  
22 proIL-beta. *Mol Cell* 10:417-426.  
23 Meduri, G.U., S. Headley, G. Kohler, F. Stentz, E. Tolley, R. Umberger, and K.  
24 Leeper. 1995. Persistent elevation of inflammatory cytokines predicts a  
25 poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent  
26 and efficient predictors of outcome over time. *Chest* 107:1062-1073.  
27 Merad, M., and J.C. Martin. 2020. Pathological inflammation in patients with  
28 COVID-19: a key role for monocytes and macrophages. *Nat Rev Immunol*  
29 20:355-362.  
30 Misawa, T., M. Takahama, T. Kozaki, H. Lee, J. Zou, T. Saitoh, and S. Akira. 2013.  
31 Microtubule-driven spatial arrangement of mitochondria promotes  
32 activation of the NLRP3 inflammasome. *Nat Immunol* 14:454-460.  
33 Monteiro, H.P., and C.C. Winterbourn. 1988. The superoxide-dependent transfer  
34 of iron from ferritin to transferrin and lactoferrin. *Biochem J* 256:923-928.  
35 Monteiro, L.B., G.G. Davanzo, C.F. de Aguiar, and P.M.M. Moraes-Vieira. 2020.  
36 Using flow cytometry for mitochondrial assays. *MethodsX* 7:100938.  
37 Munoz-Planillo, R., P. Kuffa, G. Martinez-Colon, B.L. Smith, T.M. Rajendiran, and G.  
38 Nunez. 2013. K(+) efflux is the common trigger of NLRP3 inflammasome  
39 activation by bacterial toxins and particulate matter. *Immunity* 38:1142-  
40 1153.  
41 Nalbandian, A., K. Sehgal, A. Gupta, M.V. Madhavan, C. McGroder, J.S. Stevens, J.R.  
42 Cook, A.S. Nordvig, D. Shalev, T.S. Sehrawat, N. Ahluwalia, B. Bikdeli, D.  
43 Dietz, C. Der-Nigoghossian, N. Liyanage-Don, G.F. Rosner, E.J. Bernstein, S.  
44 Mohan, A.A. Beckley, D.S. Seres, T.K. Choueiri, N. Uriel, J.C. Ausiello, D.  
45 Accili, D.E. Freedberg, M. Baldwin, A. Schwartz, D. Brodie, C.K. Garcia,  
46 M.S.V. Elkind, J.M. Connors, J.P. Bilezikian, D.W. Landry, and E.Y. Wan.  
47 2021. Post-acute COVID-19 syndrome. *Nat Med* 27:601-615.  
48 Nicholls, J.M., L.L. Poon, K.C. Lee, W.F. Ng, S.T. Lai, C.Y. Leung, C.M. Chu, P.K. Hui,  
49 K.L. Mak, W. Lim, K.W. Yan, K.H. Chan, N.C. Tsang, Y. Guan, K.Y. Yuen, and

- 1 J.S. Peiris. 2003. Lung pathology of fatal severe acute respiratory  
2 syndrome. *Lancet* 361:1773-1778.
- 3 Ntyonga-Pono, M.P. 2020. COVID-19 infection and oxidative stress: an under-  
4 explored approach for prevention and treatment? *Pan Afr Med J* 35:12.
- 5 Patton, L.M., B.S. Saggart, N.K. Ahmed, J.A. Leff, and J.E. Repine. 1995. Interleukin-  
6 1 beta-induced neutrophil recruitment and acute lung injury in hamsters.  
7 *Inflammation* 19:23-29.
- 8 Perricone, C., E. Bartoloni, R. Bursi, G. Cafaro, G.M. Guidelli, Y. Shoenfeld, and R.  
9 Gerli. 2020. COVID-19 as part of the hyperferritinemic syndromes: the  
10 role of iron depletion therapy. *Immunol Res* 68:213-224.
- 11 Phillips, R.J., M. Lutz, and B. Premack. 2005. Differential signaling mechanisms  
12 regulate expression of CC chemokine receptor-2 during monocyte  
13 maturation. *J Inflamm (Lond)* 2:14.
- 14 Pohanka, M. 2013. Role of oxidative stress in infectious diseases. A review. *Folia*  
15 *Microbiol (Praha)* 58:503-513.
- 16 Prabhakar, N.R., Y.J. Peng, and J. Nanduri. 2020. Hypoxia-inducible factors and  
17 obstructive sleep apnea. *J Clin Invest* 130:5042-5051.
- 18 Rahman, I., and W. MacNee. 1999. Lung glutathione and oxidative stress:  
19 implications in cigarette smoke-induced airway disease. *Am J Physiol*  
20 277:L1067-1088.
- 21 Rodrigues, T.S., K.S.G. de Sa, A.Y. Ishimoto, A. Becerra, S. Oliveira, L. Almeida, A.V.  
22 Goncalves, D.B. Perucello, W.A. Andrade, R. Castro, F.P. Veras, J.E. Toller-  
23 Kawahisa, D.C. Nascimento, M.H.F. de Lima, C.M.S. Silva, D.B. Caetite, R.B.  
24 Martins, I.A. Castro, M.C. Pontelli, F.C. de Barros, N.B. do Amaral, M.C.  
25 Giannini, L.P. Bonjorno, M.I.F. Lopes, R.C. Santana, F.C. Vilar, M.  
26 Auxiliadora-Martins, R. Luppino-Assad, S.C.L. de Almeida, F.R. de Oliveira,  
27 S.S. Batah, L. Siyuan, M.N. Benatti, T.M. Cunha, J.C. Alves-Filho, F.Q. Cunha,  
28 L.D. Cunha, F.G. Frantz, T. Kohlsdorf, A.T. Fabro, E. Arruda, R.D.R. de  
29 Oliveira, P. Louzada-Junior, and D.S. Zamboni. 2021. Inflammasomes are  
30 activated in response to SARS-CoV-2 infection and are associated with  
31 COVID-19 severity in patients. *J Exp Med* 218:
- 32 Rutkowska-Zapala, M., M. Suski, R. Szatanek, M. Lenart, K. Weglarczyk, R.  
33 Olszanecki, T. Grodzicki, M. Strach, J. Gasowski, and M. Siedlar. 2015.  
34 Human monocyte subsets exhibit divergent angiotensin I-converting  
35 activity. *Clin Exp Immunol* 181:126-132.
- 36 Satis, H., H.S. Ozger, P. Aysert Yildiz, K. Hizel, O. Gulbahar, G. Erbas, G. Aygencel, O.  
37 Guzel Tunccan, M.A. Ozturk, M. Dizbay, and A. Tufan. 2021. Prognostic  
38 value of interleukin-18 and its association with other inflammatory  
39 markers and disease severity in COVID-19. *Cytokine* 137:155302.
- 40 Sekhar, R.V., S.V. McKay, S.G. Patel, A.P. Guthikonda, V.T. Reddy, A.  
41 Balasubramanyam, and F. Jahoor. 2011. Glutathione synthesis is  
42 diminished in patients with uncontrolled diabetes and restored by dietary  
43 supplementation with cysteine and glycine. *Diabetes Care* 34:162-167.
- 44 Shah, A. 2020. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A  
45 Potential Drug Target in the Treatment of COVID-19. *Front Immunol*  
46 11:1021.
- 47 Sharma, D., and T.D. Kanneganti. 2016. The cell biology of inflammasomes:  
48 Mechanisms of inflammasome activation and regulation. *J Cell Biol*  
49 213:617-629.


- 1 Shaw, S., K.P. Rubin, and C.S. Lieber. 1983. Depressed hepatic glutathione and  
2 increased diene conjugates in alcoholic liver disease. Evidence of lipid  
3 peroxidation. *Dig Dis Sci* 28:585-589.
- 4 Shi, C.S., N.R. Nabar, N.N. Huang, and J.H. Kehrl. 2019. SARS-Coronavirus Open  
5 Reading Frame-8b triggers intracellular stress pathways and activates  
6 NLRP3 inflammasomes. *Cell Death Discov* 5:101.
- 7 Shi, J., Y. Zhao, K. Wang, X. Shi, Y. Wang, H. Huang, Y. Zhuang, T. Cai, F. Wang, and  
8 F. Shao. 2015. Cleavage of GSDMD by inflammatory caspases determines  
9 pyroptotic cell death. *Nature* 526:660-665.
- 10 Shimizu, H., Y. Kiyohara, I. Kato, T. Kitazono, Y. Tanizaki, M. Kubo, H. Ueno, S.  
11 Ibayashi, M. Fujishima, and M. Iida. 2004. Relationship between plasma  
12 glutathione levels and cardiovascular disease in a defined population: the  
13 Hisayama study. *Stroke* 35:2072-2077.
- 14 Slaats, J., J. Ten Oever, F.L. van de Veerdonk, and M.G. Netea. 2016. IL-1beta/IL-  
15 6/CRP and IL-18/ferritin: Distinct Inflammatory Programs in Infections.  
16 *PLoS Pathog* 12:e1005973.
- 17 Tan, K.S., K.O. Lee, K.C. Low, A.M. Gamage, Y. Liu, G.Y. Tan, H.Q. Koh, S. Alonso, and  
18 Y.H. Gan. 2012. Glutathione deficiency in type 2 diabetes impairs cytokine  
19 responses and control of intracellular bacteria. *J Clin Invest* 122:2289-  
20 2300.
- 21 Tang, Y., J. Liu, D. Zhang, Z. Xu, J. Ji, and C. Wen. 2020. Cytokine Storm in COVID-  
22 19: The Current Evidence and Treatment Strategies. *Front Immunol*  
23 11:1708.
- 24 Tardif, J.C., N. Bouabdallaoui, P.L. L'Allier, D. Gaudet, B. Shah, M.H. Pillinger, J.  
25 Lopez-Sendon, P. da Luz, L. Verret, S. Audet, J. Dupuis, A. Denault, M.  
26 Pelletier, P.A. Tessier, S. Samson, D. Fortin, J.D. Tardif, D. Busseuil, E.  
27 Goulet, C. Lacoste, A. Dubois, A.Y. Joshi, D.D. Waters, P. Hsue, N.E. Lopor, F.  
28 Lesage, N. Sainturel, E. Roy-Clavel, Z. Bassevitch, A. Orfanos, G.  
29 Stamatescu, J.C. Gregoire, L. Busque, C. Lavallee, P.O. Hetu, J.S. Paquette,  
30 S.G. Deftereos, S. Levesque, M. Cossette, A. Nozza, M. Chabot-Blanchet,  
31 M.P. Dube, M.C. Guertin, G. Boivin, and C. Investigators. 2021. Colchicine  
32 for community-treated patients with COVID-19 (COLCORONA): a phase 3,  
33 randomised, double-blinded, adaptive, placebo-controlled, multicentre  
34 trial. *Lancet Respir Med*
- 35 Toldo, S., R. Bussani, V. Nuzzi, A. Bonaventura, A.G. Mauro, A. Cannata, R. Pillappa,  
36 G. Sinagra, P. Nana-Sinkam, P. Sime, and A. Abbate. 2021. Inflammasome  
37 formation in the lungs of patients with fatal COVID-19. *Inflamm Res* 70:7-  
38 10.
- 39 Traverso, N., R. Ricciarelli, M. Nitti, B. Marengo, A.L. Furfaro, M.A. Pronzato, U.M.  
40 Marinari, and C. Domenicotti. 2013. Role of glutathione in cancer  
41 progression and chemoresistance. *Oxid Med Cell Longev* 2013:972913.
- 42 Tschopp, J., and K. Schroder. 2010. NLRP3 inflammasome activation: The  
43 convergence of multiple signalling pathways on ROS production? *Nat Rev*  
44 *Immunol* 10:210-215.
- 45 Wang, K., W. Chen, Z. Zhang, Y. Deng, J.Q. Lian, P. Du, D. Wei, Y. Zhang, X.X. Sun, L.  
46 Gong, X. Yang, L. He, L. Zhang, Z. Yang, J.J. Geng, R. Chen, H. Zhang, B. Wang,  
47 Y.M. Zhu, G. Nan, J.L. Jiang, L. Li, J. Wu, P. Lin, W. Huang, L. Xie, Z.H. Zheng,  
48 K. Zhang, J.L. Miao, H.Y. Cui, M. Huang, J. Zhang, L. Fu, X.M. Yang, Z. Zhao, S.  
49 Sun, H. Gu, Z. Wang, C.F. Wang, Y. Lu, Y.Y. Liu, Q.Y. Wang, H. Bian, P. Zhu,

- 1 and Z.N. Chen. 2020. CD147-spike protein is a novel route for SARS-CoV-2  
2 infection to host cells. *Signal Transduct Target Ther* 5:283.
- 3 WHO. 2021. WHO Coronavirus (COVID-19) Dashboard. In World Health  
4 Organization.
- 5 Wilk, A.J., A. Rustagi, N.Q. Zhao, J. Roque, G.J. Martinez-Colon, J.L. McKechnie, G.T.  
6 Ivison, T. Ranganath, R. Vergara, T. Hollis, L.J. Simpson, P. Grant, A.  
7 Subramanian, A.J. Rogers, and C.A. Blish. 2020. A single-cell atlas of the  
8 peripheral immune response in patients with severe COVID-19. *Nat Med*  
9 26:1070-1076.
- 10 Williams, D.M., G.R. Lee, and G.E. Cartwright. 1974. The role of superoxide anion  
11 radical in the reduction of ferritin iron by xanthine oxidase. *J Clin Invest*  
12 53:665-667.
- 13 Wu, C., X. Chen, Y. Cai, J. Xia, X. Zhou, S. Xu, H. Huang, L. Zhang, X. Zhou, C. Du, Y.  
14 Zhang, J. Song, S. Wang, Y. Chao, Z. Yang, J. Xu, X. Zhou, D. Chen, W. Xiong,  
15 L. Xu, F. Zhou, J. Jiang, C. Bai, J. Zheng, and Y. Song. 2020. Risk Factors  
16 Associated With Acute Respiratory Distress Syndrome and Death in  
17 Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.  
18 *JAMA Intern Med* 180:934-943.
- 19 Xu, H., S.A. Chitre, I.A. Akinyemi, J.C. Loeb, J.A. Lednický, M.T. McIntosh, and S.  
20 Bhaduri-McIntosh. 2020. SARS-CoV-2 viroporin triggers the NLRP3  
21 inflammatory pathway. *bioRxiv* 2020.2010.2027.357731.
- 22 Yong, S.J. 2021. Long COVID or post-COVID-19 syndrome: putative  
23 pathophysiology, risk factors, and treatments. *Infect Dis (Lond)* 1-18.
- 24 Zamorano Cuervo, N., and N. Grandvaux. 2020. ACE2: Evidence of role as entry  
25 receptor for SARS-CoV-2 and implications in comorbidities. *Elife* 9:
- 26 Zhang, D., R. Guo, L. Lei, H. Liu, Y. Wang, Y. Wang, H. Qian, T. Dai, T. Zhang, Y. Lai, J.  
27 Wang, Z. Liu, T. Chen, A. He, M. O'Dwyer, and J. Hu. 2021. Frontline  
28 Science: COVID-19 infection induces readily detectable morphologic and  
29 inflammation-related phenotypic changes in peripheral blood monocytes.  
30 *J Leukoc Biol* 109:13-22.
- 31 Zheng, J., Y. Wang, K. Li, D.K. Meyerholz, C. Allamargot, and S. Perlman. 2021.  
32 Severe Acute Respiratory Syndrome Coronavirus 2-Induced Immune  
33 Activation and Death of Monocyte-Derived Human Macrophages and  
34 Dendritic Cells. *J Infect Dis* 223:785-795.
- 35 Zhou, R., A.S. Yazdi, P. Menu, and J. Tschopp. 2011. A role for mitochondria in  
36 NLRP3 inflammasome activation. *Nature* 469:221-225.
- 37 Zhou, Z., C. Huang, Z. Zhou, Z. Huang, L. Su, S. Kang, X. Chen, Q. Chen, S. He, X.  
38 Rong, F. Xiao, J. Chen, and S. Chen. 2021. Structural insight reveals SARS-  
39 CoV-2 ORF7a as an immunomodulating factor for human CD14(+)   
40 monocytes. *iScience* 24:102187.

41

42

## 1 FIGURES



2

3 **Figure 1. Phenotypic changes in circulating monocyte subsets during**

4 **COVID-19.** (A) Representative FACS plots showing the distribution of the

5 monocyte subsets defined by CD14 and CD16 markers in COVID-19 patients.

6 Percentage of CD14<sup>low</sup>CD16<sup>+</sup> (B) and CD14<sup>high</sup>CD16<sup>-</sup> (C) monocytes among

7 circulating mononuclear myeloid cells


8 (HLADR<sup>+</sup>CD2<sup>-</sup>CD3<sup>-</sup>CD19<sup>-</sup>CD20<sup>-</sup>CD56<sup>-</sup>CD66<sup>-</sup>) were compared between

9 healthy controls (HC, n=21) and COVID-19 patients (n = 38). Data are

10 presented as median with interquartile range. The geometric mean

1 fluorescence intensity (gMFI) of HLA-DR (**D**) and CCR2 (**E**) expression on  
2 CD14<sup>high</sup>CD16<sup>-</sup> monocytes was compared between HC (n=21) and COVID-19  
3 patients (n=38). Percentage of CD14<sup>high</sup>CD16<sup>-</sup> (**F**) and CD14<sup>low</sup>CD16<sup>+</sup> (**G**)  
4 monocytes as well as MFI of HLA-DR (**H**) and CCR2 (**I**) expression on  
5 CD14<sup>high</sup>CD16<sup>-</sup> monocytes is compared between COVID-19 patients  
6 experiencing mild symptoms (n=22) versus moderate to severe forms of  
7 COVID-19 (n=16). Data were analyzed using the Mann-Whitney test. \*\*\*P  
8 <0.001, \*\*\*\*P <0.0001; *ns*, not significant.

9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24



1

2 **Figure 2. COVID-19 patients exhibit a high frequency of monocytes**

3 **displaying FLICA<sup>+</sup>ASC-speck formation.** (A) Plasma levels of IL-18 were

4 compared between healthy control (HC) donors (n=9) and COVID-19 patients

5 (n=39). Lines represent median values and interquartile ranges. (B) PBMCs

6 were incubated with the fluorochrome inhibitor of caspase-1/4/5 (FLICA) and

7 the geometric mean fluorescence intensity (gMFI) of FLICA within the

8 CD14<sup>high</sup>CD16<sup>-</sup> monocyte subset was compared between HC (n=21) and

9 COVID-19 patients (n=38). Data are presented as median with interquartile

10 range. (C) PBMCs from HC (n=24) and COVID-19 patients (n=32) were

11 incubated with FLICA, stained for monocyte identification and intracellular

12 ASC and acquired by using Imaging flow cytometry. Representative images

13 showing respectively: CD14, CD16, ASC and FLICA fluorescence followed by

14 a composite image containing brightfield (BF), and the fluorescence of ASC

15 and FLICA merged, were selected from a COVID-19 patient. (D) The

1 percentage of monocytes showing spontaneous FLICA<sup>+</sup>ASC-Speck formation  
2 was quantified after application of Modulation\_Morphology (M11,Ch11)\_11-  
3 ASC feature, followed by Bright Detail Similarity R3\_MC\_11-ASC\_2-FLICA,  
4 inside the CD14<sup>high</sup>CD16<sup>-</sup> monocyte gate, by using IDEAS software. Lines  
5 represent median values and interquartile ranges. (E) Spearman correlations  
6 between plasma levels of IL-18 and the percentage of ASC-speck<sup>+</sup>FLICA<sup>+</sup>  
7 CD14<sup>high</sup>CD16<sup>-</sup> monocytes in COVID-19 patient samples. Percentage of ASC-  
8 speck<sup>+</sup>FLICA<sup>+</sup> cells (F) and plasma levels of IL-18 (G) were compared  
9 between COVID-19 patients experiencing mild symptoms (n=18 and n=28,  
10 respectively) and moderate to severe cases of COVID-19 (n=13 and n=12,  
11 respectively). Lines represent median values and interquartile ranges. Data  
12 were analyzed using the Mann-Whitney test. \*P <0.05, \*\*P <0.01, \*\*\*\*P  
13 <0.0001.

14

15

16

17

18

19

20


21

22

23

24

25



1

2

3 **Figure 3. Effects of the NLRP3 inhibitor MCC950 and colchicine on**

4 **cytokine secretion by COVID-19 PBMCs. IL-1 $\beta$  (A), IL-6 (B) and TNF $\alpha$  (C)**

5 levels from supernatants of healthy control (HC, n=7) or COVID-19 patients

6 PBMCs (n=16) after a 4 hr incubation at 37C, were determined by multi-

7 analyte flow assay kit. Lines represent median values and interquartile

8 ranges. Alternatively, COVID-19 cells were pretreated with the NLRP3

9 inhibitor, MCC950 (10 $\mu$ M; n=9) or colchicine (10 $\mu$ M; n=7) during the

10 incubation period, and IL-1 $\beta$  (D), IL-6 (E) and TNF $\alpha$  (F) levels were measured

11 in the culture supernatants by multi-analyte flow assay kit. Numbers represent


12 the median values and interquartile ranges. Data were analyzed using the

13 Mann-Whitney test. \*\*P <0.01, \*\*\*P <0.001, \*\*\*\*P <0.0001; ns, not significant.

14

15

16



1

2 **Figure 4. Measures of oxidative stress in COVID-19 patients.** Plasma  
3 levels of ferritin (A), Catalase (B), Superoxide dismutase (SOD) (C), Trolox  
4 (D) Iron (E) and Lipid peroxidation (F) were compared between healthy  
5 control (HC) donors (n=10-12) and COVID-19 patients (n=20-40). Lipid  
6 peroxidation (LAA) (G) and mitochondrial superoxide (MitoSOX) (H) in  
7 CD14<sup>high</sup>CD16<sup>-</sup> monocytes was measured by flow cytometry in PBMC  
8 samples from HC (n=22) and COVID-19 patients (n=40). Data are expressed  
9 as the geometric mean fluorescence intensity (gMFI) over average of HC. (I)

1 Intracellular glutathione (GSH) levels in PBMC lysates from HC (n=17) and  
2 COVID-19 patients (n=27) were determined by analytic enzymatic assay as  
3 described in Methods. Data are presented as median values and interquartile  
4 ranges and analyzed using Mann-Whitney test. \*P <0.05, \*\*P <0.01, \*\*\*P  
5 <0.001, \*\*\*\*P <0.0001; *ns*, not significant.

6

7

8

9

10

11

12

13

14

15

16

17

18

19


20

21

22

23

24



1


2 **Figure 5. Oxidative stress and inflammasome responses are associated**  
 3 **in COVID-19 patients. (A)** Multi-parameter Spearman's correlation analysis  
 4 of PBMC samples from healthy control (HC) and COVID-19 patients (\*P <0.05  
 5 or less). **(B)** PBMCs from COVID-19 patients (n=6) were incubated with  
 6 Mitotracker Red, stained for intracellular ASC and acquired by means of  
 7 Imaging flow cytometry. Representative images showing respectively: BF  
 8 (brightfield), Mitotracker Red, ASC and a composite image of both Mitotracker  
 9 Red and ASC markers merged, were selected from a CD14<sup>+</sup>ASC-speck<sup>neg</sup>  
 10 gate (top panel) and a CD14<sup>+</sup>ASC-speck<sup>pos</sup> gate (bottom panel). **(C)** The  
 11 percentage of monocytes showing the diffuse pattern for Mitotracker Red  
 12 shown in B (top panel) *versus* the aggregated staining profile as shown in B  
 13 (bottom panel) was determined after application of Major Axis

1 Intensity\_M04\_Ch4 x Mean Pixel\_M04\_Ch4 features inside both CD14<sup>+</sup>ASC-  
2 speck<sup>neg</sup> and CD14<sup>+</sup>ASC-speck<sup>pos</sup> gates using IDEAS software. **(D)** Loss of  
3 mitochondrial membrane potential ( $\Delta\Psi_m$ ) was determined by the change of  
4 Mitotracker Red gMFI staining on CD14<sup>+</sup>ASC-speck<sup>neg</sup> and CD14<sup>+</sup>ASC-  
5 speck<sup>pos</sup> subsets. Data are presented as median values and interquartile  
6 ranges and were analyzed using the Mann-Whitney test (\*\*P < 0.01). **(E-F)**  
7 Spearman correlations between FLICA and MitoSOX **(E)** or FLICA and LAA  
8 **(F)** levels within CD14<sup>high</sup>CD16<sup>-</sup> monocytes from COVID-19 patients. **(G-H)**  
9 Spearman correlations between FLICA and MitoSOX **(G)** or FLICA and LAA  
10 levels **(H)** on CD14<sup>high</sup>CD16<sup>-</sup> monocytes obtained from COVID-19 patients  
11 grouped based on their disease severity in patients experiencing mild  
12 symptoms (top panel, green) or moderate to severe cases of COVID-19  
13 (bottom panel, red). Each dot represents a correspondent value from each  
14 patient. *ns*, not significant.

15

16

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



16 **Figure 6. Exposure of human healthy control monocytes to SARS-CoV-2**  
17 ***in vitro* induces IL-1 $\beta$  by a mechanism involving both inflammasome**  
18 **activation and lipid peroxidation. (A)** Elutriated monocytes isolated from  
19 fresh healthy donors PBMCs were co-cultured with live SARS-CoV-2 (USA-  
20 WA1/2020) at distinct MOIs (0.1, 0.5 or 1), media only (mock) or heat  
21 inactivated SARS-CoV-2 (HI Cov-2) and IL-1 $\beta$  levels were measured in the  
22 culture supernatants after 24 hours by ELISA. Data represent the means  $\pm$   
23 SEM of triplicate samples. Statistical significance was assessed by one-way  
24 ANOVA analysis for the indicated experimental conditions. \*P <0.05, \*\*\*\*P  
25 <0.0001. (B) Healthy donor monocytes were incubated with SARS-CoV-2 at

1 MOI of 1 and treated or not with the NLRP3 inhibitor, MCC950 (10 $\mu$ M) or the  
2 lipid peroxidation inhibitor, Fer-1 (10 $\mu$ M). IL-1 $\beta$  levels were measured in  
3 culture supernatants after 24 hours by ELISA. Data represent the means  $\pm$   
4 SEM of 2 independent experiments pooled with 5-6 replicates. Statistical  
5 significance was assessed by one-way ANOVA analysis for the indicated  
6 experimental conditions. \*\*P < 0.01, \*\*\*P <0.001, \*\*\*\*P <0.0001.

7

8

9

10

11

12

13

14

15

16

17

18


19

20

21

22

23



**Figure 7. Measurements associated with inflammatory responses persist**

**in COVID-19 patients after short-term recovery.** Oxidative stress and

inflammatory markers were compared between HCs and COVID-19 patients

after recovery (median of 52 days IQR: 47.3-75.3, after infection onset) as

follows: (A) Percentage of patrolling CD14<sup>low</sup>CD16<sup>+</sup> monocyte subset, (B)

CCR2 expression on monocytes, (C) HLADR expression on monocytes, (D)

Percentage of ASC-speck<sup>+</sup> CD14<sup>high</sup>CD16<sup>-</sup> cells, (E) caspase-1 activity

measured by FLICA staining, (F) lipid peroxidation (LAA) and (G)

mitochondrial superoxide (MitoSOX) in classical monocytes, (H) intracellular

glutathione levels in PBMC. (I) IL-18 levels were measured in plasma

1 samples. (J-L) Spontaneous *in vitro* IL-1 $\beta$ , IL-6 and TNF $\alpha$  production by  
2 PBMC, respectively. Lines represent median values and interquartile ranges.  
3 Closed symbols indicate hospitalized patients (inpatients) and open symbols  
4 denote mild disease outpatients. Data were analyzed using the Mann-Whitney  
5 test. \*P <0.05, \*\*\*P <0.01, \*\*\*\*P <0.01; ns, not significant.

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

1 **TABLE 1. COVID-19 participant characteristics (% or median values with**  
 2 **IQR in parenthesis).**

<b>Characteristic</b>	<b>Mild</b>	<b>Moderate- Severe</b>	<b>Recovered</b>
N	31	16	16
Age – y	63 (50-67.5)	62.5 (55.8-69.5)	48.5 (37-57.5)
Female – no. (%)	16 (52)	7 (44)	12 (75)
BMI (Kg/m <sup>2</sup> )	31 (28.6-39.5)	28.7 (24-36.4)	31.5 (25.4-48.8)
<b>Race – no. (%)</b>			
White	13 (42)	5 (31)	9 (56)
African American	14 (45)	8 (50)	3 (19)
Other	4 (13)	3 (19)	4 (25)
*ANC (x10 <sup>9</sup> cells/L)	3.0 (2.4-4.6)	7.3 (5.1-9.9)	3.6 (3.1-4.9)
*ALC (x10 <sup>9</sup> cells/L)	1.3 (1.1-2.0)	1.2 (0.9-1.8)	1.9 (1.4-2.6)
Time from symptoms to lab draw (Days)	9 (6-13.5)	10 (8.8-11.5)	52 (47.3-75.3)
<b>Comorbidities – no. (%)</b>			
Hypertension	18 (58)	12 (75)	8 (50)
Diabetes mellitus	14 (45)	6 (38)	4 (25)
COPD/Asthma	5 (16)	5 (31)	4 (25)
Renal Disease	3 (10)	2 (13)	0 (0)
<b>Treatment – no. (%)</b>			
Remdesivir	6 (19)	11 (69)	4 (25)
Dexamethasone	2 (6)	4 (25)	3 (19)

3

4 \* ANC = Absolute neutrophil count, ALC = Absolute leukocyte count.

5

6

7

8

9

10

- 1 **TABLE 2. Plasma biomarkers measurement in healthy controls (HC)**
- 2 **versus COVID-19 patients (median values with IQR in parenthesis).**

<b>Biomarker (pg/ml)</b>	<b>HC</b>	<b>COVID-19</b>	<b>p-value</b>
<b>N</b>	<b>13</b>	<b>29</b>	<b>NA</b>
<b>IFN-<math>\gamma</math></b>	<b>5.34 (3.2-7.8)</b>	<b>9.17 (4.9-24.6)</b>	<b>0.06</b>
<b>IL-10</b>	<b>0.36 (0.24-0.65)</b>	<b>0.90 (0.60-2.33)</b>	<b>0.003</b>
<b>IL-12p70</b>	<b>0.40 (0.22-0.76)</b>	<b>0.31 (0.19-1.07)</b>	<b>0.94</b>
<b>IL-2</b>	<b>0.43 (0.29-0.47)</b>	<b>0.24 (0.13-0.40)</b>	<b>0.21</b>
<b>IL-6</b>	<b>0.48 (0.24-0.60)</b>	<b>6.07 (1.06-19.1)</b>	<b>&lt;0.001</b>
<b>IL-8</b>	<b>2.41 (1.53-2.89)</b>	<b>4.36 (2.55-6.07)</b>	<b>0.03</b>
<b>TNF-<math>\alpha</math></b>	<b>1.50 (1.21-1.77)</b>	<b>3.02 (1.67-4.73)</b>	<b>0.002</b>
<b>IL-27</b>	<b>1410 (1095-1733)</b>	<b>2295 (1511-3770)</b>	<b>0.002</b>
<b>CRP (mg/L)</b>	<b>1.81 (1.55-7.45)</b>	<b>83.4 (9.30-187.9)</b>	<b>0.005</b>
<b>SAA (mg/L)</b>	<b>7.85 (3.98-9.96)</b>	<b>230.8 (14.9-404.8)</b>	<b>&lt;0.001</b>
<b>sCD14 (mg/L)</b>	<b>1.36 (1.23-1.66)</b>	<b>1.75 (1.38-2.31)</b>	<b>0.05</b>
<b>IL-6R<math>\alpha</math></b>	<b>32960 (30321-37174)</b>	<b>38853 (34737-44826)</b>	<b>0.02</b>
<b>D-dimer (ng/ml)</b>	<b>303 (214-579)</b>	<b>1452 (566-2502)</b>	<b>0.002</b>
<b>Ferritin (ng/ml)</b>	<b>101 (42.7-297)</b>	<b>1100 (173-1650)</b>	<b>0.007</b>

- 3 \* **p-value** when Mann-Whitney was applied.